

March 2026

CURRICULUM VITAE - ROY TAYLOR MBE

Personal Details	2
Main Appointments	2
Research, Teaching & Managerial Appointments	3
Research Council & Wellcome Trust Grants Awarded	5
Other Research Grants	6
Supervision of PhD Studies	8
Supervision of MD Studies	9
Prizes and Awards	3
Original Papers	9
Reviews, Editorials and Book Chapters	30
Short Commentaries	37
Invited Lectures	40
Clinical Work	60
Particular Achievements	61

Personal Details

Civil status: Married/4 children

Civil honour: MBE 2023

Qualifications: BSc Hons University of Edinburgh 1973
MB ChB University of Edinburgh 1976
MRCP 1978
MD University of Edinburgh 1985
FRCP (Lond) 1989
FRCP (Edin) 1991

Main Appointments

Present: Emeritus Professor of Medicine and Metabolism, Newcastle University

Previous appointments

1977-78 Senior House Officer, Ninewells Hospital, Dundee.

1978-79 Registrar to Professor KG Lowe and Dr RW Newton, Ninewells Hospital, Dundee.

1979-81 Registrar rotation, Newcastle University Hospitals.

1981-84 MRC Training Fellow, honorary senior registrar to Professor KGMM Alberti and honorary senior research associate of the University of Newcastle upon Tyne.

1984-85 First Assistant in Metabolic Medicine, Professorial Medical Unit, Newcastle upon Tyne.

1985-91 Senior Lecturer in Medicine and Honorary Consultant Physician, Royal Victoria Infirmary and Princess Mary Maternity Hospital, Newcastle upon Tyne.

1990-91 Visiting Professor of Medicine, Yale Medical School, New Haven, USA. Sabbatical period Sept 1990 - Aug 1991.

1991-96 Reader in Metabolic Medicine, University of Newcastle upon Tyne and Honorary Consultant Physician, Royal Victoria Infirmary and Princess Mary Maternity Hospital, Newcastle upon Tyne.

1996-2022 Professor of Medicine and Metabolism, Newcastle University & Honorary Consultant Physician, Newcastle upon Tyne Hospitals

2005-21 Director of Newcastle Magnetic Resonance Centre

Prizes and Awards

Distinction in Obstetrics and Gynaecology 1976
Lawson Gifford prize in Obstetrics and Gynaecology 1976
Distinction in Paediatrics 1976
Croom Lectureship Royal College of Physicians of Edinburgh 1988
RD Lawrence Lectureship of British Diabetic Association 1991
Albert Renold Fellowship - European Association for the Study of Diabetes 1990-91
Samuel Lenard Simpson Fellowship - Royal College of Physicians 1990-1991
Honyman-Gillespie Lecture - Edinburgh Medical School – 1992
Arnold Bloom Lecture – Diabetes UK 2005
Chennai MDRF Gold Medal Oration on Diabetic Retinopathy 2005
Banting Lecture Diabetes UK 2012
Life Membership of the British Association of Retinal Screening 2012
Harry Keen Rank Nutrition Prize Lecture Diabetes UK 2016
Samuel Gee Lecture of The Royal College of Physicians 2017
Sir Robert W Philip Lecture of The Royal College of Physicians of Edinburgh 2021
MBE awarded for services to diabetes research; King Charles' 2024 New Year Honours
Robert Turner Prize for Research Impact – Diabetes UK 2023
International Rank Prize for Nutrition 2024
The Claude Bernard Prize Lecture and Medal – EASD 2024

Prizes awarded to trainees

R Pandit: Percival J Hay Memorial Prize 1999, North of England Ophthalmological Society for “Mydriasis and Glaucoma: Exploding the Myth”.

R Pandit: Bausch & Lomb Ophthalmology Prize 2000 for “Quality Assurance in Screening for Diabetic Retinopathy”.

P Carey: Diabetes UK/ Servier Prize 2002: “Change in Muscle Glycogen After a Mixed Meal in Type 2 Diabetes”.

P Carey: Dewar research prize 2003.

B Ravikumar: 2004 SKB Award for Best Presentation at post-ADA meeting.

Dr A Jovanovic: 2007 GSK Young Diabetologist Award “Metabolic basis of the second meal effect”.

Dr B Ravikumar: 2007 Myra Sim Prize for best published paper, Royal College of Physicians of Edinburgh.

Dr K Hollingsworth: 2009 ICM Poster Prize.

Dr EL Lim: 2010 Association of Northern Physicians Best Oral Presentation.

Dr K Hodson: 2011 Northern Region Frank Stabler Prize for best trainee.

Dr S Steven: 2013 Best Presentation at Institute of Cellular Medicine Annual Meeting.

Dr S Steven: 2013 Anglo Danish Dutch Best Oral Presentation.

Ms S Cassidy: 2014 Best Poster Oral Presentation, Diabetes UK Annual Scientific Meeting.

Ms S Cassidy: 2015 Nick Hales Award for Best Oral Presentation, Diabetes UK Annual Scientific Meeting.

Dr D O’Hogain: 2016 ICM Directors’ Day Prize for Best Oral Presentation.

Dr Lucia Rehackova: Best presentation in psychology, Diabetes UK Annual Professional Meeting 2018.

Research, Teaching & Managerial Appointments

Research

Member of NHS Advisory group on ‘Type 2 Diabetes Path to Remission’ program 2019 ongoing
Chairman of DiGEST Steering Committee, University of Cambridge 2018-2024
Member of the LEGEND (Low EnerGy diEt iN adolescents with obesity and type 2 Diabetes) trial steering group 2024-
Chairman of DIASTOLIC Steering Committee, University of Leicester 2017-2000
Member of UK Government Scientific Advisory Committee on Nutrition group to evaluate low carbohydrate diets 2017-2020
Member of Diabetes UK Research Committee October 2012-2017
Member of Scientific Review Panel DDZ (German Diabetes Research Centre), Dusseldorf 2013 & 2020
Member of MRC College of Experts 2006-2011
Member of Faculty Ethics Committee 2007-2012
Secretary, Dynamic Spectroscopy Group, International Society for Magnetic Resonance in Medicine. 2008-2009
Member of Scientific Advisory Board, Programme National de Recherche sur le Diabete, INSERM / CNRS, France 2004-2009
Member of Research Grant Panel, Italian Ministry for Education University and Research (MIUR) 2002-2005; 2007-2013
Member of Medical Research Council Steering Committee for the POPADAD Study 1997-2006
Chairman, NovoNordisk Project Grants Committee 1993-1996
Member of Medical Research Council Systems Board Grants Committee B: 1988-1992
Associate Editor, Diabetic Medicine: 1987-1995
Scientific Editor, European Journal of Clinical Investigation 1995-2000
Review Editor, International Diabetes Monitor: 1989-
Member of Editorial Advisory Council of Journal of Endocrinological Investigation: 1990-1996
Member of Scientific Committee of International Symposia on Insulin Receptors and Insulin Action 1989-2000
Member of Programme Committee for ADA 1993 and EASD 1999
Referee for Journal of Clinical Investigation, New England Journal of Medicine, British Medical Journal, Lancet, Cell Metabolism, Cell Reports, Clinical Endocrinology, Hepatology, Diabetes, Diabetologia, Diabetes Care, American Journal of Physiology, Clinical Science, European Journal of Clinical Investigation, Journal of Endocrinology, British Journal of Clinical Pharmacology
Grants referee for Medical Research Council, BBSRC, The Wellcome Trust, NIHR, Diabetes UK, British Heart Foundation, Agence Nationale de Recherche (INSERM), The Italian Ministry of Health, The Birthright Trust, Hadwen Trust

Teaching

External examiner for PhD and MD theses, Oxford, Cambridge, London, Nottingham, Dublin, Southampton, Liverpool, Ulster, Sydney, Otago, Lund, Maastricht and Yale Universities
Director of Undergraduate Teaching, RVI Trust 1996-1999
Director of Undergraduate Clinical Skills Course 1987-1998

Acting Chairman of Curriculum Implementation Committee April-August 1994
 Vice-chairman of Implementation Working Party for the New Clinical Curriculum 1993-1994
 Member of Faculty Teaching Committee 1985-1996
 Member of Board of Studies for MB BS course 1996-1998
 Secretary of RVI Teaching and Research Committee 1993-1996

Managerial / Administrative

Director of Newcastle Magnetic Resonance Centre 2005-2021
 President of Newcastle Branch of Diabetes UK 2014 -2020
 Director of Newcastle Magnetic Resonance Centre, 2005-2021
 President of British Association of Retinal Screeners 2001-2007
 Member of Medical Advisory Board of Pregnancy Sickness Support 2006-
 Head of General Medical Unit 1996-2003
 Director, Regional Mobile Retinal Screening Service, 1987-2014
 Member of DoH English Diabetic Retinopathy Screening Advisory Committee 2003-2015
 Member of National Service Framework working group on diabetic eye disease 2000-2001
 Chairman, British Diabetic Association Committee on Retinal Camera Screening: 1989-2000
 RCP representative National Retinopathy Screening Committee 1999-2000
 Member, Senate of University of Newcastle upon Tyne, 1992-1995
 Secretary of Association of North of England Physicians, 1994-
 Member, NHS / University Liaison committee 1997-2001
 Member, Northern Regional Working Party on Diabetes 1986-1996
 RVI representative on Newcastle Local Medical Committee 1986-1990
 Deputy Director Research & Development at Royal Victoria Infirmary 1993-1998

Research Council & Wellcome Trust Grants Awarded

1983-1985	Medical Research Council Project Grant. Human adipocyte insulin binding and sensitivity in insulin resistant states. £46,000. Sole Investigator.
1986-1988	Medical Research Council Project Grant. Insulin sensitivity of muscle in non-insulin dependent diabetes. £45,000. Sole Investigator.
1988-1991	Wellcome Trust Project Grant. Investigation of the genetic basis of NIDDM using monoclonal anti-insulin receptor antibodies. £49,000. Sole Investigator.
1990-1991	Medical Research Council Project Grant. Comparison of NMR spectroscopy and direct biochemical methods in the investigation of glycogen metabolism in normal and diabetic man. £15,000. Sole Investigator.
1992-1996	Medical Research Council Special Project Grant. Studies of NIDDM. £500,000. Co-investigator with KGMM Alberti, SJ Yeaman, L Agius and D Turnbull.
1995-1998	Medical Research Council Special Project Grant. Studies on the molecular basis of NIDDM. £650,000. Co-investigator with KGMM Alberti, SJ Yeaman, L Agius and DM Turnbull.
1999-2001	Wellcome Trust Project Grant. The dynamics of postprandial substrate storage in normal and diabetic man. £170,000. Principal Investigator (co-

- applicant Prof P Morris).
 2001-2003 Wellcome Trust Project Grant. The dynamics of postprandial substrate storage in normal and diabetic man. £147,000. Principal Investigator (co-applicant Prof P Morris).
 2004-2008 Wellcome Trust Programme Grant. The dynamics of postprandial lipid and carbohydrate interaction in liver and muscle of normal and diabetic subjects. £662,148. Principal Investigator (co-applicant Prof P Morris).
 2006-2008 MRC Project Grant. Pathogenetic Mechanisms and Potential Therapeutic Targets For Fatigue in Primary Biliary Cirrhosis. £198,426 (coapplicant with Prof D Jones and Dr J Newton).

Other Research Grants

- 1981-1983 Newcastle upon Tyne Scientific and Research Committee. Characterization of adipocyte and monocyte insulin receptors in man. £18,000. Sole Investigator.
 1985-1986 Newcastle upon Tyne Scientific and Research Committee. Muscle insulin sensitivity in normal and diabetic man. £14,000. Sole Investigator.
 1985-1990 British Diabetic Association Group Grant. £200,000. Co-investigator.
 1986-1987 Newcastle upon Tyne Scientific and Research Committee. Hepatic and peripheral tissue insulin sensitivity in normal ageing. £16,000. Sole Investigator.
 1986-1989 British Diabetic Association. Northern Region mobile retinal camera project. £54,000. Sole Investigator.
 1987-1989 Glaxo Research Division. Muscle insulin sensitivity in vivo and in vitro. £41,000. Sole Investigator.
 1988-1989 Bayer UK. Sucrose absorption and insulin sensitivity. £15,000. Sole Investigator.
 1988-1990 Newcastle University Research Committee. Indirect calorimetry in diabetes and pregnancy. £128,000. Sole Investigator.
 1989-1990 Iris Fund. Northern Region mobile retinal camera project. £18,000. Sole Investigator.
 1989-1991 Wellcome Trust Fellowship award to support Dr AB Johnson. £56,000. Principal Investigator.
 1989-1991 Glaxo Group Research. Modulation of human muscle insulin sensitivity. £96,000. Sole Investigator.
 1989-1990 Servier Laboratories. Effect of gliclazide on human muscle in vitro. £19,000. Sole Investigator.
 1991-1992 Glaxo Group Research. Modulation of human muscle glucose and fatty acid metabolism. £48,000. Sole Investigator.
 1994-1995 CellTech Laboratories. Effect of a humanised anti-TNF alpha antibody on insulin sensitivity in NIDDM associated with obesity. £38,000. Sole Investigator.
 1994-1997 NovoNordisk. Cross-over study of once daily Ultratard insulin and twice daily Insulatard insulin upon rates of hypoglycaemia and patient acceptability. £101,800. Sole Investigator.
 1994-1996 RD Lawrence Fellowship Award to support Dr S Hurel. £79,900. Principal Investigator.
 1995-1998 British Diabetic Association. Further studies of cultured human muscle. £26,000. Principal Investigator.
 1998-1999 British Diabetic Association. Effect of TNF on insulin action in cultured human muscle cells. £33,000. Sole Investigator.
 1998-1999 NovoNordisk Foundation. Hepatic glucose output in normal and diabetic

- man. £47,000. Sole Investigator.
- 1999-2000 Lilly Research Foundation. Insulin signalling in cultured human muscle cells from subjects with Type 2 diabetes. £11,919. Sole Investigator.
- 2001-2003 Eli Lilly. Normalisation of postprandial metabolism in type 2 diabetes: Use of short acting insulin analogues. £88,677. Sole Investigator.
- 2001-2004 Eli Lilly. Characterisation of the natural history of diabetic retinopathy during modern diabetes management. £94,214. Sole Investigator.
- 2002-2003 Takeda UK. Effect of enhancing insulin sensitivity upon postprandial hepatic glucose output. £54,000. Sole Investigator.
- 2004-2006 NovoNordisk Foundation Fellowship Award. Is the abnormal postprandial suppression of hepatic glucose production in type 2 diabetes reversible by decreasing intrahepatic triglyceride stores? £97,000.
- 2004-2006 NovoNordisk Foundation. Is the abnormal postprandial suppression of hepatic glucose production in type 2 diabetes reversible by decreasing intrahepatic triglyceride stores? £12,500. Joint Investigator.
- 2004 Magnetic Resonance Centre capital award from The Cookson Trust £50,000.
- 2004 Magnetic Resonance Centre capital award from Newcastle Healthcare Charity £0.25 million.
- 2004 Magnetic Resonance Centre capital award from Northern Rock Foundation £500,000.
- 2004 Magnetic Resonance Centre capital award from Strategic Research Infrastructure 2 Funds £1,300,000.
- 2004 Magnetic Resonance Centre capital allocation from Northumbria Laboratories funds £700,000.
- 2005 Magnetic Resonance Centre capital award from The Barclay Foundation £30,000.
- 2005 Magnetic Resonance Centre capital award from Strategic Research Infrastructure 3 Funds £900,000.
- 2005 Magnetic Resonance Centre capital award from OneNorthEast £1 million.
- 2005 William Leech Foundation support for named lectureship in MR Physics £70,000.
- 2006-2007 Hepatic Encephalopathy. Special Trustees.
- 2007-2009 Diabetes UK RD Lawrence Fellowship for Dr M Trenell. Increased physical activity and glucose control: developing a framework for clinical application in type 2 diabetes. £160,000.
- 2008-2009 Newcastle Special Trustees. The effect of increased physical activity upon liver fat content in people with non-alcoholic fatty liver disease. £47,698.
- 2008-2010 Dunhill Medical Trust. Eliminating Periodontal Infection in Patients with Type 2 Diabetes Mellitus: Impact on Glycaemic Control and Quality of Life. £138,260. Co-Investigator.
- 2009-2010 Diabetes UK. Effect of change in pancreas and liver fat content upon beta cell function and hepatic insulin action during weight loss in type 2 diabetes. £126,000. Principal Investigator.
- 2010-2011 Novartis. A single-centre, double-blind, randomised, placebo-controlled, parallel-group study to assess the effect of 24 weeks of treatment with Vildagliptin on insulin sensitivity and its underlying mechanisms in patients with type 2 diabetes treated with metformin. £790,959. Principal Investigator.
- 2012-2015 European Foundation for the study of Diabetes. Physical Changes in the Liver and Pancreas during Reversal of Type 2 Diabetes. Euro 95,000. Principal Investigator.

- 2010-2012 NIHR Biomedical Research Centre. MR studies of Function and Metabolism in Ageing. £130,000. Principal Investigator.
- 2010-2012 BUPA Foundation Fatigue in Sub-Clinical Hypothyroidism. £123,104. Co-Investigator.
- 2010-2012 Wellbeing of Women. Lipid metabolism in normal pregnancy: A MR pilot study. £19195. Principal Investigator.
- 2014-2019 Diabetes UK. Diabetes Remission Clinical Trial (DiRECT). £2.4million. Co-Chief Investigator.
- 2014-2015 North East Diabetes Trust. The impact of dietary intervention on reversal of diabetes and maternal liver fat in gestational diabetes (WELLBABE). £16,000. Principal Investigator.
- 2017-2020 DiRECT Extension of Follow Up to 5 years. £500,000. Co-Principle investigator.
- 2017-2022 Diabetes UK. Reversal of Type 2 diabetes Upon Normalisation of Energy intake in non-obese people (ReTUNE). £515,389. Principal Investigator.

Supervision of PhD Studies

- 1981-1983 'Studies of the insulin receptor.' (Omar Al-Attas) Thesis accepted by University of Newcastle upon Tyne October 1983.
- 1982-1985 'Insulin receptor binding and biological potency of sulphated insulin.' (Stefan Zeuzem). Accepted Summa cum laude by University of Frankfurt am Main, 1986.
- 1983-1987 'Studies of insulin action in muscle' (Soheli Chowdhury). Thesis accepted by University of Newcastle upon Tyne, 1987.
- 1985-1989 'Insulin sensitivity of human muscle' (Mary Argyraki). Thesis accepted by University of Newcastle upon Tyne, 1989.
- 1988-1991 'Application of indirect calorimetry to the investigation of human metabolism' (Brendan G. Cooper). Thesis accepted 1992.
- 1990-1994 'Modulation of insulin sensitivity in muscle' (Judith Webster). Thesis accepted 1995.
- 1994-1997 'Molecular mechanism of insulin insensitivity in NIDDM' (Steven Hurel). Thesis accepted 1997.
- 2001-2005 'Normalisation of postprandial metabolism in type 2 diabetes' (B Ravikumar). Thesis accepted 2009.
- 2007-2010 'Physical activity, exercise and ageing' (L Papaconstantinou). Thesis accepted 2011.
- 2007-2010 'Mitochondrial abnormalities in type 2 diabetes' (Ee Lin Lim). Thesis accepted 2012.
- 2008-2011 'Physical activity, exercise and non-alcoholic fatty liver disease' (K Hallsworth). Thesis accepted 2012.
- 2011-2014 'Reversal of type 2 diabetes' (Sarah Steven). Thesis accepted 2016.
- 2012-2015 'MR Studies of the heart in metabolic disease' (Sophie Cassidy) Thesis accepted 2016.
- 2015-2018 'The Metabolic Basis of Long Term Reversal of Type 2 Diabetes' (Sviatlana Zhyzhneuskaya) Thesis accepted 2022.

Supervision of MD Studies

- 1986-1988 'Ageing and insulin sensitivity' (David L Broughton). Thesis accepted by University of Newcastle upon Tyne, 1992.
- 1987-1991 'Muscle insulin action in NIDDM' (Andrew B Johnson). Thesis accepted by University of Newcastle upon Tyne 1994.
- 1992-1998 'Insulin sensitivity in PCOS' (Philippa Marsden). Thesis accepted by University of Newcastle upon Tyne 1999.
- 1999-2003 'Postprandial metabolism in type 2 diabetes' (Peter Carey). Thesis accepted by University of Newcastle upon Tyne 2006.
- 2001-2004 'Characterisation of the natural history of diabetic retinopathy' (C Arun). Thesis accepted by University of Newcastle upon Tyne 2006.
- 2005-2007 'Postprandial triglyceride distribution and storage in type 2 diabetes' (Ana Jovanovic). Thesis accepted by Newcastle University 2009.
- 2011-2014 'Effect of DPPIV inhibition on insulin sensitivity' (Mavin Macauley). Thesis accepted by Newcastle University 2016.
- 2013-2018 'The Metabolic basis of Gestational diabetes' (Ken Hodson). Thesis accepted by Newcastle University 2018.

Supervision of MPhil Studies

- 1999-2000 'Hepatic glucose production in type 2 diabetes' (Parag Singal). Thesis accepted by University of Newcastle upon Tyne 2003.
- 2012-2013 'Wide-field Imaging and OCT versus clinical evaluation of patients referred from Diabetic Retinopathy Screening' (Vina Manjunath). Thesis 2014.

Membership of Specialist Societies

1. British Diabetic Association - 1980
2. European Association for the Study of Diabetes - 1981
3. Thyroid Club - 1980
4. Biochemical Society - 1985
5. American Diabetes Association - 1986
6. Association of Physicians of Great Britain and Ireland - 1991
7. International Society for Magnetic Resonance in Medicine – 1991
8. British Association of Retinal Screeners (co-founder) 2001 and Life Membership awarded 2013

Original Papers

1. Butterworth AE, Sturrock RF, Houba V, Taylor R. Antibody dependent cell mediated damage to ⁵¹Cr labelled schistosomula. *Clin Exp Immunol* 1976; 25:96-102
2. Taylor R. Gastrocolic fistula secondary to drug induced gastric ulceration. *Postgrad Med Journal* 1978; 54: 283-284
3. Taylor R, Morgan JM, Davie RM. Renal amyloidosis secondary to mild psoriatic arthropathy. *Brit J Clin Practice* 1981; 35:410-414

4. Worth R, Taylor R, Anderson J, Alberti KGMM. Jet injection of insulin: comparison with conventional syringe injection. *Brit Med Journal* 1980; 281:713-714
5. Taylor R, Clark FC, Griffith ID, Weeke J. Prospective study of the effect of fenclofenac on thyroid function tests. *Brit Med Journal* 1980; 281:911-912
6. Taylor R, Home PD, Alberti KGMM. Plasma free insulin profiles after injection of insulin by syringe and jet injector. *Diabetes Care* 1981; 4:377-379
7. Taylor R, Arze R, Gokal R, Stoddart JC. Cephaloridine encephalopathy. *Brit Med Journal* 1981; 283:409-410
8. Taylor R. Interviewing: the need for continuing education. *Colloquy* 1981; IX:14-15
9. Taylor R, Waddel A, Dale G, Tunbridge WMG. Cortisol creatinine ratio in normal pregnancy. *Horm Metab Res* 1982; 14:279
10. Taylor R, Taylor AEM, Diffey BL, Hindson TC. A placebo controlled trial of UVA photo therapy for uraemic pruritus. *Nephron* 1983; 33:14-16
11. Taylor R, Hutton C, Weeke J, Clark F. Fenclofenac - secondary effects upon the pituitary-thyroid axis. *Clinical Endocrinology* 1983; 19:683-692
12. Taylor R, Isles TE, MacClaren S, Newton R. Metabolic profiles during treatment with glibipizide and glibenclamide. *Diabetologia Croatica* 1983; 12:279-292
13. Taylor R, Proctor SJ, James O, Clark F, Alberti KGMM. The relationship between human adipocyte and monocyte insulin binding. *Clinical Science* 1984; 67:139-142
14. Ponchner M, Taylor R, Heine R, Alberti KGMM. *In vivo* insulin sensitivity and monocyte insulin binding during glibenclamide therapy. *Hormone Metab Res* 1984; 16: 208
15. Zeuzem S, Taylor R, Agius L, Albisser M, Alberti KGMM. Differential binding of sulphated insulin to adipocytes and hepatocytes. *Diabetologia* 1984; 27: 184-188
16. Taylor R, Husband DJ, Marshall SM, Tunbridge WMG, Alberti KGMM. Adipocyte insulin binding and insulin sensitivity in brittle diabetes. *Diabetologia* 1984; 27:441-446
17. Taylor R, Heine R, Collins J, James O, Alberti KGMM. Insulin sensitivity in hepatic cirrhosis. *Hepatology* 1985; 5:64-71
18. Taylor R, McCulloch AJ, Zeuzem S, Clark F, Alberti KGMM. Insulin secretion, adipocyte insulin binding and insulin action in thyrotoxicosis. *Acta Endocrinologia* 1985; 109:96-103
19. Zeuzem S, Taylor R. Assessment of human adipocyte glucose uptake using the physiological substrate D-glucose. *Scand J Clin Lab Med* 1985; 45:545-551
20. Spiro JG, Scott S, MacMillan J, Diffey BL, Hindson TC, Taylor R, Taylor AEM, Downey A. Treatment of uraemic pruritus with blue light. *Photodermatology* 1985; 2:319-321

21. Zeuzem S, Taylor R, Agius L, Albisser AM, Alberti KGMM. Biological effects of sulphated insulin in adipocytes and hepatocytes. *Molecular and Cellular Biochemistry* 1985; 68:161-168
22. Gill GV, Husband DJ, Wright PD, Sharpe G, Taylor R, Walford S, Marshall SM, Alberti KGMM. Treatment of severe brittle diabetes with Infusaid implantable insulin infusion pumps. *Diabetes Research* 1986; 3:135-137
23. Taylor R, Heaton A, Hetherington CS, Alberti KGMM. Adipocyte insulin binding and insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. *Metabolism* 1986; 35:430-435
24. Taylor R, Heatherington CS, Alberti KGMM. Changes in tissue insulin sensitivity in previously 'brittle' diabetics. *Horm Metab Res* 1986; 18:493-494
25. Pinewska DM, McCulloch AJ, Bramble M, Taylor R, Record CO, Alberti KGMM. Glucose turnover in compensated hepatic cirrhosis. *Horm Metab Res* 1986; 18:834-837
26. Whittaker J, Hammond V, Taylor R, Alberti KGMM. Effect of monensin on insulin interactions with isolated hepatocytes. *Biochem J* 1986; 234:463-468
27. Soos M, Taylor R, Siddle K. Insulin-inhibitory and insulin-like effects of monoclonal antibodies. *Biochem Soc Trans* 1986; 14:317-318
28. Gray CS, Taylor R, French JM, Alberti KGMM, Venables GS, James OFW, Shaw DA, Cartlidge NEF, Bates D. Previously unrecognised diabetes and hyperglycaemia in acute stroke. *Diabetic Medicine* 1987 4:237-240
29. Taylor R, Soos MA, Wells AM, Argyraki M, Siddle KS. Insulin-like and insulin inhibitory effects of monoclonal antibodies for different epitopes on the human insulin receptor. *Biochem J* 1987; 242:123-129
30. Siddle KS, Soos MA, O'Brien RM, Gandeston RH, Taylor R. Monoclonal antibodies as probes of the structure and function of insulin receptors. *Biochem Soc Trans* 1987; 15:47-51
31. Kruszynska YT, Petranyi G, Home PD, Taylor R, Alberti KGMM. Muscle enzyme activity and insulin sensitivity in Type I (insulin dependent) diabetes. *Diabetologia* 1986; 29:699-705
32. Chowdhury SA & Taylor R. Insulin sensitivity of glucose metabolism in obese soleus muscle strip. *Biochem Soc Trans* 1986; 14:1171-1172
33. Chowdhury SA, Agius L & Taylor R. Glucose and pyruvate metabolism in soleus strips. *Biochem Soc Trans* 1986; 14: 1170-1171
34. Broughton DL, Alberti KGMM, Taylor R. Insulin sensitivity and ageing. *Gerontology* 1987; 33:357-362
35. Marshall SM, Home PD, Taylor R, Alberti KGMM. Continuous subcutaneous insulin versus injection therapy: A randomised cross-over trial under usual diabetic clinic conditions. *Diabetic Medicine* 1987; 4:521-525

36. Marshall SM, Taylor R, Home PD. Peripheral insulin sensitivity and adipocyte insulin binding and action after subcutaneous insulin injection therapy and continuous subcutaneous insulin infusion. *Acta Endocrinol* 1989; 117:417-427
37. Chowdhury SA & Taylor R. Glucose metabolism by soleus muscle in neonatal streptozotocin induced diabetes. *Biochem Soc Trans* 1987; 15: 929
38. Chowdhury SA & Taylor R. Soleus muscle insulin sensitivity in diabetes. *Biochem Soc Trans* 1987; 15:930-931
39. Samad AHB, Ty-Willing TS, Alberti KGMM, Taylor R. Effects of BAYm 1099, a new alpha-glucosidase inhibitor, on long term and acute metabolic control in diet treated non-insulin dependent diabetes mellitus. *Diabetes Care* 1988; 11:337-344
40. Kellett H, Collier A, Taylor R, Sawyers JSA, Benson C, Baird D, Clarke BF. Hyperandrogenism, insulin resistance, acanthosis nigricans and SLE associated with insulin receptor antibodies. *Metabolism* 1988; 37:656-659
41. M'banya JC, Thomas TH, Wilkinson R, Alberti KGMM, Taylor R. Hypertension and hyperinsulinaemia: A relationship in diabetes but not essential hypertension. *Lancet* 1: 1088; 733-734
42. Thomas TH, Mbanya JC, Taylor R, Alberti KGMM, Wilkinson R. Hypertension and diabetes mellitus: erythrocyte electrolytes and the effect of captopril treatment. *J Human Hypertension* 1988; 2:229-234
43. Taylor R, Hetherington CS, Tolley S. Biological activity of despentapeptide insulin, a non-aggregating insulin analogue, upon adipocytes and hepatocytes. *Horm Metab Res* 1989; 21:249-252
44. Heaton A, Taylor R, Johnston DG, Ward MK, Wilkinson R, Alberti KGMM. Hepatic and peripheral insulin action in chronic renal failure before and during CAPD. *Clinical Science* 1989; 77:383-388
45. Argyraki M, Wright PD, Venables CW, Proud G, Taylor R. Study of human skeletal muscle in vitro: Effect of NEFA supply on glucose storage. *Metabolism* 1989; 38:1183-1187
46. Atkinson L, Taylor R. Acute neurotoxic and hepatotoxic features of over-exposure to paint fumes. *Postgraduate Medical Journal* 1989; 65:559-562
47. Chowdhury SA, Taylor R. Insulin sensitivity in experimental cirrhosis. *Molecular and Cellular Biochemistry* 1989; 89:69-72
48. Cassidy DM, Pratt DA, Taylor R, Alberti KGMM, Laker MF. Capillary column gas chromatography and mass spectrometry for the determination of the fatty acid composition of human adipose tissue. *J Chromatography* 1989; 491:1-13
49. M'banya J-C, Thomas T, Taylor R, Alberti KGMM, Wilkinson R. Increased proximal tubular sodium absorption in hypertensive patients with type 2 diabetes. *Diabetic Medicine* 1989; 6:614-620
50. Taylor R, Smith NM, Angus B, Home CHW, Dunlop W. Return of fertility after twelve years of autoimmune ovarian failure. *Clinical Endocrinology* 1989; 31:305-308

51. Carr SA, Mbanya JC, Thomas T, Kearey P, Taylor R, Alberti KGMM, Wilkinson R. Increase in glomerular filtration rate in insulin dependent diabetic patients with elevated erythrocyte sodium-lithium counter-transport. *New England Journal of Medicine* 1990; 322:500-505
52. Johnson A, Argyraki M, Thow J, Broughton DL, Jones IR, Miller M, Taylor R. Effects of intensive dietary treatment on insulin stimulated skeletal muscle glycogen synthase in non-insulin dependent diabetes. *Diabetic Medicine* 1990; 7:420- 428
53. Cooper B, Taylor R, Alberti KGMM, Gibson GJ. Lung function in diabetes mellitus. *Respiratory Medicine* 1990; 84:235-239
54. Johnson AB, Argyraki M, Thow JC, Jones IR, Broughton DL, Miller M & Taylor R. Impaired activation of skeletal muscle glycogen synthase in NIDDM is unrelated to the degree of obesity. *Metabolism* 1991; 40: 252-260
55. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KGMM. Treatment with bezafibrate lowers plasma glucose concentrations in patients with poorly controlled non-insulin dependent diabetes mellitus. *Diabetes Care* 1990; 13:855-863
56. Broughton DL, James OFW, Alberti KGMM, Taylor R. Peripheral and hepatic insulin sensitivity in healthy elderly subjects. *European Journal Clinical Investigation* 1991; 21:13-21
57. Taylor R, Lovelock L, Tunbridge WMG, Alberti KGMM, Brackenridge R, Stevenson P, Young E. Comparison of non-mydratic Polaroid retinal photography with ophthalmoscopy in 2,150 patients. *British Medical Journal* 1990; 301:1243-1247 doi: 10.1136/bmj.301.6763.1243
58. Johnson A, Argyraki M, Jones IR, Taylor R. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting NIDDM subjects. *Diabetic Medicine* 1991; 8:243-253
59. Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane insulin. *Diabetic Medicine* 1990; 7:795-799
60. Pears J, Jung RT, Browning MCK, Taylor R, Burchell A. Reactive hypoglycaemia in association with disordered islet function and abnormal hepatic glucose-6-phosphatase activity: Response to diazoxide. *Diabetic Medicine* 1991; 8:268-271
61. Cooper BG, McClean JA, Taylor R. Evaluation of the Deltatrac indirect calorimeter by gravimetric gas injection and alcohol burning. *Clinical Physics and Physiological Measurement* 1991; 12:333-341
62. Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in NIDDM. *Diabetic Medicine* 1992; 9:61-65
63. Johnston AB, Argyraki M, Thow JC, Cooper BG, Fulcher G, Taylor R. Effect of increased non-esterified fatty acid supply upon glucose metabolism and skeletal

muscle glycogen synthase activity in normal man. *Clinical Science* 1992; 82: 219-226

64. Taylor R, Price TP, Rothman D, Shulman RG, Shulman GI. Validation of ¹³C-NMR measurement of muscle glycogen by comparison with biopsy and direct biochemical assessment. *Magnetic Resonance in Medicine* 1992; 27:13-20
65. Rutherford PA, Thomas T, Carr SJ, Taylor R, Wilkinson R. Kinetics of sodium-lithium countertransport activity in patients with uncomplicated type 1 diabetes. *Clinical Science* 1992; 82:291-299
66. Rutherford PA, Thomas T, Carr SJ, Taylor R, Wilkinson R. Changes in erythrocyte sodium-lithium countertransport kinetics in diabetic nephropathy. *Clinical Science* 1992; 82:301-307
67. Njenga E, Lind T, Taylor R. Five year audit of blood glucose control during labour in insulin dependent diabetes. *Diabetic Medicine* 1992; 9:567-570, 1992
68. Broughton DL, Webster JM, Taylor R. The pathophysiology of abnormal glucose tolerance does not differ between elderly and young subjects. *European Journal of Clinical Investigation* 1992; 22:582-590
69. Johnson AB, Webster JM, Sum C-F, Heseltine L, Argyraki M, Cooper BG, Taylor R. The impact of metformin therapy upon hepatic glucose production and skeletal muscle glycogen synthase activity in overweight non-insulin dependent diabetic patients. *Metabolism* 1993; 42:1217-1222
70. Taylor R, Price TB, Rothman DL, Shulman RG, Shulman GI. Direct measurement of change in muscle glycogen concentration after a mixed meal in normal subjects. *American Journal of Physiology* 1993; 265:E224-229
71. Wells AM, Sutcliffe IC, Johnson AB, Taylor R. Abnormal activation of fibroblast glycogen synthesis in familial NIDDM: Evidence for an abnormality specific to glucose metabolism. *Diabetes* 1993; 42:583-589
72. Ahmed T, Nelson RG, Taylor R. Increased insulin clearance in cystic fibrosis. *Metabolism* 1994; 43:163-167
73. Rutherford PA, Thomas T, Taylor R, Wilkinson R. Nephropathy and changes in sodium-lithium countertransport kinetics in Type II diabetes. *Journal of Human Hypertension* 1994; 8:29-35
74. Price TB, Taylor R, Mason GM, Rothman DL, Shulman GI, Shulman RG. Turnover of human muscle glycogen during low-intensity exercise. *Medicine and Science in Sports and Exercise* 1994; 26:983-989
75. Price TB, Rothman DL, Taylor R, Avison MJ, Shulman GI, Shulman RG. Human muscle glycogen resynthesis after exercise: Insulin dependent and independent phases. *J Appl Physiol* 1994; 76:104-111
76. Taylor R, Foster B, Kyne D, Vanderpump M. Insulin therapy for NIDDM: Effect upon quality of life and metabolic control. *Diabetic Medicine* 1994; 11:551-557

77. Dowd A, Thomas TH, Taylor R, Wilkinson R. Erythrocyte sodium/lithium countertransport activity is related to membrane fluidity in insulin dependent diabetes mellitus. *Diabetologia* 1994; 37:394-400
78. Marsden P, Murdoch A, Taylor R. Severe insulin resistance in adipocytes from PCOS subjects. *Metabolism* 1994; 43:1536-1542
79. Langdown JV, Williamson D, Beresford CH, Gibb I, Taylor R, Deacon-Smith R. A new haemoglobin beta chain variant, Hb Tyne [β 5(A2)PRO->SER] *Hemoglobin* 1994; 18:333-336
80. Heseltine L, Webster JM, Taylor R. Modulation of lipolysis in human adipocytes by adenosine receptor agonists. *Molecular and Cellular Biochemistry* 1995; 144: 147-151
81. Barriocanal L, Borthwick A, Hurel S, Taylor R. The defect in activation of glycogen synthase in muscle of non-insulin dependent diabetic subjects reflects a defect in protein phosphatase 1 activation. *Diabetic Medicine* 1995; 12:1110-1115
82. Stewart MW, Kyne-Grzebralski DA, Marshall SM, Taylor R. Are diaries worthwhile in the diabetic clinic? *Practical Diabetes* 1995; 12:232-233
83. Taylor R. Successful management of hyperemesis gravidarum using steroid therapy. *Quarterly Journal of Medicine* 1996; 89: 103-107
84. Gascoigne A, Appleton A, Taylor R, Batchelor A, Cook S. Catastrophic circulatory collapse following re-expansion pulmonary oedema. *Resuscitation* 1996; 31:265-269
85. Taylor R, Magnusson I, Rothman DL, Cline GW, Cuomo A, Cobelli C, Shulman GI. Direct assessment of liver glycogen storage and regulation of glucose homeostasis after a mixed meal in normal subjects. *Journal of Clinical Investigation* 1996; 97:126-132
86. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol change overall insulin sensitivity in diet treated type II diabetic patients? *Diabetes Care* 1996; 19:559-563
87. Phillips DIW, Borthwick AC, Stein C, Taylor R. Fetal growth and insulin resistance in adult life: Relationship between glycogen synthase activity in adult skeletal muscle and birthweight. *Diabetes Medicine* 1996; 13:325-329
88. Marsden PJ, Murdoch AP, Taylor R. Adipocyte insulin action during the menstrual cycle. *Human Reproduction* 1996; 11:968-974
89. Webster JM, Heseltine L, Taylor R. *In vitro* effect of the adenosine agonist GR79236 on the insulin sensitivity of glucose utilisation in rat soleus and human rectus abdominis muscle. *Biochem Biophys Acta* 1996; 1316:109-113
90. Ofei F, Hurel S, Newkirk J, Taylor R. Effects of an engineered human TNF α antibody (CDP571) on insulin sensitivity and glycemic control in patients with non-insulin dependent diabetes mellitus. *Diabetes* 1996; 45:881-885
91. Phillips DIW, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, Taylor R. Intramuscular triglyceride and muscle insulin sensitivity: Evidence for a relationship in non-diabetic subjects. *Metabolism* 1996; 45:947-950

92. Webster JM, Heseltine L, Taylor R. Dose and time characteristics of sulphonylurea effect upon human and rat skeletal muscle. *Diabetes Nutrition and Metabolism* 1996; 9:115-121
93. Taylor R. Practical community screening for diabetic retinopathy using the mobile retinal camera: report of a 12 centre study. *Diabetic Medicine* 1996; 13:946-952
94. Turnbull AJ, Mitchison HC, Peaston RTP, Lai LC, Bennett MK, Taylor R, Bassendine MP. The prevalence of hereditary haemochromatosis in a diabetic population in North-East England. *Quarterly Journal of Medicine* 1997; 90:271-275
95. Taylor R, Broadbent D, Greenwood R, Harding S. Mobile Retinal Screening in Britain. *Diabetic Medicine* 1998; 15: 334-337
96. Whittaker PG, Lee CH, Cooper BC, Taylor R. Evaluation of phenylalanine and tyrosine metabolism in late human pregnancy. *Metabolism* 1999; 48:849-852
97. Marsden PJ, Murdoch AP, Taylor R. Adipocyte insulin action following ovulation in polycystic ovarian syndrome. *Human Reproduction* 1999; 14:2216-2222
98. Carron Brown S, Kyne-Grzebalski D, Mwangi B, Taylor R. Effect of management policy upon 120 Type 1 diabetic pregnancies: Policy decisions in practice. *Diabetic Medicine* 1999; 16:573-578
99. Kyne-Grzebalski D, Wood L, Marshall, SM, Taylor R. Episodic hyperglycaemia in well controlled Type 1 diabetic women in pregnancy: A potential cause of macrosomia. *Diabetic Medicine* 1999; 16:702-706
100. Rutter MK, Wilcox E, Easton J, Skinner J, Taylor R. Improving the early management of blood glucose in emergency admissions with chest pain. *Practical Diabetes* 2001; 18:75-78
101. Marsden PJ, Murdoch AP, Taylor R. Adipocyte insulin action in hypogonadotropic hypogonadism. *Human Reproduction* 2000; 15:1672-1678
102. Whittaker PG, Lee CH, Taylor R. Whole body protein kinetics in women. The effect of pregnancy and type 1 diabetes during anabolic stimulation. *American Journal of Physiology* 2000; 279:E978-E988
103. Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L. Appropriate insulin regimes for type 2 diabetes: A multicentre randomised crossover study. *Diabetes Care* 2000; 23:1612-1618
104. Pandit R, Taylor R. Mydriasis and glaucoma: Exploding the myth. *Diabetic Medicine* 2000; 17:693-699
105. Marsden PJ, Murdoch AP, Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. *Clinical Endocrinology* 2001; 55:191-199. PMID: 11531925
106. Halse R, Pearson SL, McCormack JG, Yeaman SJ, Taylor R. Effects of tumor necrosis factor alpha on insulin action in cultured human muscle cells. *Diabetes* 2001; 50:1102-1109. PMID: 11334414
107. Pandit R, Taylor R. Quality Assurance in eye screening. *Diabetic Medicine* 2002; 19:285-291. PMID: 11942999

108. Moran P, Taylor R. Management of hyperemesis gravidarum: The importance of weight loss as a criterion for steroid therapy. *Quarterly Journal of Medicine* 2002; 95: 153-158. PMID: 11865170
109. Taylor R, Lee C, Kyne-Grzebalski D, Marshall SM, Davison JM. Clinical outcomes of pregnancy in women with type 1 diabetes. *Obstetrics & Gynecology* 2002; 99:537-541. PMID: 12039106
110. Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R. Regulation of endogenous glucose production after a mixed meal in Type 2 diabetes. *American Journal of Physiology* 2002; 283:E275-83. PMID: 12110532
111. Arun CS, Ngugi N, Taylor R. Effectiveness of screening in preventing blindness due to diabetic retinopathy. *Diabetic Medicine* 2003; 20:186-90. PMID: 12675661
112. Carey PE, Halliday J, Snaar JEM, Morris P, Taylor R. Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects. *American Journal of Physiology* 2003; 284: E286-294. PMID: 12453829
113. Dashora UK, Taylor R. Maintaining glycaemic control during high-dose prednisolone administration for hyperemesis gravidarum in Type 1 diabetes. *Diabetic Medicine* 2004; 21: 298-9. PMID: 15008846
114. Harding S, Greenwood R, Aldington S, Gibson J, Owens D, Taylor R, Kohner E, Scanlon P, Leese G. Grading and disease management in national screening for diabetic retinopathy in England and Wales. *Diabetic Medicine* 2003; 20:965-971. PMID: 14632697
115. Arun CS, Pandit R, Taylor R. Long term progression of retinopathy after initiation of insulin therapy in type 2 diabetes. *Diabetologia* 2004; 47:1380-84. PMID: 15309288 (IF 6.671)
116. Basu A, Dillon RDS, Taylor R, Davison JM, Marshall SM. Is normalisation of serum potassium and magnesium always necessary in Gitelman syndrome for a successful obstetric outcome? *British Journal of Obstetric and Gynaecology* 2004; 111:630-634. PMID: 15198796 (IF 3.728)
117. Singhal P, Caumo A, Cobelli C, Taylor R. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. *Metabolism* 2005; 54:79-84
118. Al-Bermani A, Desha YH, Morgan J, Soobrah R., Symonds CS, Taylor R. Management of incidental hyperglycaemia in acute medical emergencies. *Diabetic Medicine* 2005; 22:937-941. PMID: 15975111
119. Ravikumar B, Carey PE, Snaar JEM, Deelchand DK, Cook DB, Neely RD, English PT, Firbank MJ, Morris PG, Taylor R. Real time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. *Am J Physiol* 2005; 288: E789-97. PMID: 15572652 (IF 3.838)
120. Advani A, Taylor R. Life-threatening hypokalaemia on a low-carbohydrate diet associated with previously undiagnosed primary hyperaldosteronism. *Diabet Med* 2005; 22:1605-7. PMID: 162419928 (IF 3.152)

121. Arun CS, Young D, Batey D, Shotton M, Mitchie D, Stannard K, Taylor R. Establishing an ongoing quality assurance in retinal screening programme. *Diabet Med* 2006; 23: 629-34. PMID: 16759304 (IF 3.115)
122. Carey PE, Gerrard J, Cline GW, Dalla Man C, English PT, Firbank MJ, Cobelli C, Taylor R. Acute inhibition of lipolysis does not affect post-prandial suppression of endogenous glucose production. *Am J Physiol* 2005; 289: 941-947. PMID: 15998660 <http://ajpendo.physiology.org/cgi/reprint/00195.2005v1> (IF 3.838)
123. Savage DB, Zhai L, Ravikumar B, Choi CS, Snaar JE, McGuire AC, Wou S-E, Medina-Gomez G, Kim S, Bock CB, Segvich DM, Vidal-Puig A, Wareham NJ, Shulman GI, Karpe F, Taylor R, Pederson BA, Roach PJ, O'Rahilly S, DePaoli-Roach AA. A Prevalent Variant in PPP1R3A Impairs Glycogen Synthesis and Reduces Muscle Glycogen Content in Humans and Mice. *PLoS Medicine* 2008; Jan 29; 5(1):e27 PMID: PMC2214798: PMID: 18232732 (IF 14.429)
124. Arun CS, Taylor R. Influence of pregnancy on long-term progression of retinopathy in patients with type 1 diabetes. *Diabetologia* 2008; 51: 1041-5. PMID: 18392803 (IF 6.671)
125. Hollingsworth KG, Newton JL, Taylor R, Blamire AM, Jones DEJ. Pilot Study of Peripheral Muscle Function in Primary Biliary Cirrhosis; Potential Implications for Fatigue Pathogenesis. *Clinical Gastroenterology and Hepatology* 2008; 6: 1041-8. PMID: 18691944 (IF 7.896)
126. Trenell MI, Hollingsworth KG, Lim EL, Taylor R. Increased daily walking improves lipid oxidation independent of changes in mitochondrial ATP synthesis in people with Type 2 diabetes. *Diabetes Care* 2008; 31:1644-1649.PMCID: PMC2494664: PMID: 18487474 (IF 11.9)
127. Ravikumar, B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. *Diabetes* 2008; 57: 2288-95. doi: 10.2337/db07-1828 (IF 8.095)
128. Belch JJ, Macuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Mathews D, Leese G, McKnight J, O'Brian I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD): a study of aspirin and antioxidants in patients with Diabetes and asymptomatic peripheral arterial disease. *Brit Med J* 2008; 337:a1840. PMID: 18927173 (IF 17.4)
129. Newton JL, Hollingsworth KG, Taylor R, El-Sharkawy AM, Khan ZU, Pearce R, Sutcliffe K, Okonkwo O, Davidson A, Burt J, Blamire AM, Jones D. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. *Hepatology* 2008; Aug; 48(2):541-9. PMID: 18563843 (IF 11.055)
130. Arun CS, Al-Bermani A, Stannard KS, Taylor R. Long term impact of retinal screening upon significant diabetes related visual impairment in the working age population. *Diabet Med* 2009; 26:489-492. PMID: 19646188 (IF 3.115)

131. Jovanovic A, Leverton E, Solanky B, Snaar JEM, Morris PEG, Taylor R. The second meal phenomenon is associated with enhanced muscle glycogen storage. *Clin Sci* 2009; 117:119–127. PMID: 19161346 (IF 5.598)
132. Al-Ozairi E, Waugh JJS, Taylor R. Termination is not the treatment of choice for severe hyperemesis gravidarum: Successful management using prednisolone. *Obstetric Medicine* 2009; 2: 34-37
133. Lim EL, Burden T, Marshall SM, Davison JM, Blott MJ, Waugh JJS, Taylor R. Intrauterine Growth Rates in Pregnancies Complicated by Type 1, Type 2 and Gestational Diabetes. *Obstetric Medicine* 2009; 2: 21-25
134. Jovanovic A, Gerrard J, Taylor R. The second meal phenomenon in type 2 diabetes. *Diabetes Care* 2009; 32:1199-1201. PMID: 19366973 (IF 11.9)
135. Hollingsworth KG, Jones DE, Aribisala BS, Thelwall PE, Taylor R, Newton JL, Blamire AM. Globus pallidus magnetization transfer ratio, T(1) and T(2) in primary biliary cirrhosis: relationship with disease stage and age. *J Magn Reson Imaging* 2009; Apr; 29:780-4. PMID: 19306399
136. Jones D, Hollingsworth K, Blamire A, Taylor R, Newton J. Abnormalities in pH Handling by Peripheral Muscle and Potential Regulation by the Autonomic Nervous System in Chronic Fatigue Syndrome. *J Int Med.* 2010; 267:394-401. PMID: 20433583 (IF 6.063)
137. Lim EL, Hollingsworth K, Thelwall P, Taylor R. Measuring the acute effect of insulin infusion on ATP turnover in human skeletal muscle using phosphorus-31 magnetic resonance saturation transfer. *NMR in Biomedicine.* 2010 Oct; 23(8):952-7. doi: 10.1002/nbm.1519. PMID 20623795 (IF 3.044)
138. Jones DE, Hollingsworth K, Fattkhova G, MacGowan G, Taylor R, Blamire A, Newton J. Impaired Cardiovascular Function in Primary Biliary Cirrhosis. *Am J Physiol Gastrointest Liver Physiol* 2010; 298: G764-73. PMID: 20133949 (IF 3.798)
139. Newton J, Hollingsworth K, Taylor R, Blamire A, Jones DE Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis. *J Hepatol* 2010; 53(1):155-61. PMID: 20447719 (IF 11.336)
140. Hollingsworth KG, Jones DEJ, Taylor R, Frith J, Blamire AM, Newton JL. Impaired cerebral autoregulation in primary biliary cirrhosis: implications for the pathogenesis of cognitive decline. *Liver International* 2010; 30: 878-85. PMID: 20492494 (IF 4.85)
141. Hollingsworth KG, Jones DEJ, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. *European J Clin Invest* 2010 Jul; 40(7):608-15. doi: 10.1111/j.1365-2362.2010.02310.x. PMID: 20497461
142. Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in type 2 diabetes prevents the beneficial

pioglitazone effect on liver fat content. *Diabet Med* 2010; 27:150-156. PMID: 20546257

143. Chen MJ, Jovanovic A, Taylor R. Utilizing the Second-Meal Effect in Type 2 Diabetes: Practical Use of a Soya-Yogurt Snack. *Diabetes Care* 2010 Dec; 33(12): 2552-4. doi: 10.2337/dc10-0552. PMID: 21115766 (IF 11.9)
144. Steven S, Lim EL, Taylor R. Reversal of type 2 diabetes motivated by research knowledge. *Diabet Med* 2010; 27: 724-725. PMID: 20546297
145. Hayes L, Pearce MS, Firbank MJ, Walker M, Taylor R, Unwin N. Do obese but metabolically normal women differ in intra-abdominal fat and physical activity levels from those with the expected metabolic abnormalities? A cross-sectional study. *BMC Public Health*. 2010 Nov 24; 10:723. doi: 10.1186/1471-2458-10-723. PMID: 21106050 (IF 2.264)
146. Mitchell A, DeAlwis N, Collins J, Chew K, Taylor R, Schwab U, Narayanan M. Stethoscope or 'Staphoscope'? Infection by auscultation. *J Hosp Infection* 2010; 20:1-2. PMID: 20692728
147. Savelev, S; Perry, J; Bourke, S; Taylor, R; Fisher, A; Corris, P; Jary, H; Petrie, M; De Soyza, A. Volatile biomarkers of *Pseudomonas aeruginosa* in cystic fibrosis and noncystic fibrosis bronchiectasis. *Letters in Applied Microbiology* 2011; 52: 610-13
148. Lim EL, Hollingsworth KG, Smith F, Thelwall PE, Taylor R. Inhibition of lipolysis in type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates. *Clin Sci* 2011 Aug; 121(4):169-77. doi: 10.1042/CS20100611. PMID: 21388348 (IF 5.598)
149. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* 2011; 54: 2506-2514. PMID 21656330; doi: 10.1007/s00125-011-2204-7 (IF 6.671)
150. Lim EL, Hollingsworth KG, Smith F, Thelwall PE, Taylor R. Effects of Raising Muscle Glycogen Synthesis on Skeletal Muscle ATP Turnover Rate in Type 2 Diabetes. *American J Physiol Endocrinol Metab* 2011 Dec; 301(6):E1155-62. doi: 10.1152/ajpendo.00278.2011. PMID: 21917633 (IF 3.785)
151. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 2011 Sep; 60(9):1278-83. doi:10.1136/gut.2011.242073. Epub 2011 Jun 27. PMID: 21708823 (IF 14.66)
152. Thelwall PE, Taylor R, Marshall SM. Non-invasive investigation of kidney disease in type 1 diabetes by magnetic resonance imaging. *Diabetologia* 2011 Sep; 54(9):2421-9 doi: 10.1007/s00125-011-2163-z. Epub 2011 May 1. PMID: 21533898 (IF 6.671)
153. Hollingsworth KG, MacGowan GA, Morris L, Bates MG, Taylor R, Jones DE, Newton JL, Blamire AM. Cardiac torsion-strain relationships in fatigued primary biliary cirrhosis patients show accelerated aging: a pilot cross-sectional study. *J*

Appl Physiol 2012 Jun; 112(12):2043-8. doi:10.1152/jappphysiol.00195.2012. PMID: 22461446 (IF 3.838)

154. Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. *J Hepatol* 2013 Apr; 58(4):757-62. doi: 10.1016/j.jhep.2012.11.015. Epub 2012 Nov 22. PMID: 23178979 (IF 11.336)
155. Hodson K, DellaMan C, Smith FE, Thelwall PE, Cobelli C, Robson SC, Taylor R. Mechanism of insulin resistance in normal pregnancy. *Horm Metab Res* 2013 Aug; 45(8):567-71. doi: 10.1055/s-0033-1337988. Epub 2013 Apr 2. PMID: 23549674
156. Steven S, Lim EL, Taylor R. Population response to information on reversibility of type 2 diabetes. *Diabet Med* 2013 Apr; 30(4):e135-8 doi: 10.1111/dme.12116. PMID: 23320491 (IF 3.115)
157. Thelwall PE, Smith FE, Leavitt MC, Canty D, Hu W, Hollingsworth KG, Thoma C, Trenell MI, Taylor R, Rutkowski JV, Blamire AM, Quinn AG. Hepatic Cholesteryl Ester Accumulation in Lysosomal Acid Lipase Deficiency: Non-invasive Identification and Treatment Monitoring by Magnetic Resonance. *J Hepatol* 2013 Sep; 59(3), 543-549. doi: 10.1016/j.jhep.2013.04.016. Epub 2013 Apr 25. PMID: 23624251 (IF 11.336)
158. Avery L, Sniehotta FF, Denton SJ, Steen N, McColl E, Taylor R, Trenell MI. Movement as Medicine for Type 2 Diabetes: protocol for an open pilot study and external pilot clustered randomised controlled trial to assess acceptability, feasibility and fidelity of a multifaceted behavioural intervention targeting physical activity in primary care. *Trials* 2014 Feb 3;15:46. doi: 10.1186/1745-6215-15-46. PMID: 24491134
159. Skamarauskas JT, Oakley F, Smith FE, Bawn C, Dunn M, Vidler DS, Clemence M, Blain PG, Taylor R, Gamcsik MP, Thelwall PE. Noninvasive *In Vivo* Magnetic Resonance Measures of Glutathione Synthesis in Human and Rat Liver as an Oxidative Stress Biomarker. *Hepatol* 2014 Jun;59(6):2321-2330. doi: 10.1002/hep.26925. PMID: 24242936 (IF 11.336)
160. Steven S, Carey PE, Small PK, Taylor R. Reversal of Type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes. *Diabet Med* 2015 Jan; 32(1):47-53. doi: 10.1111/dme.12567. Epub 2014 Sep 12. PMID: 25132043 (IF 3.115)
161. Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R, Day CP, Trenell MI. Non-alcoholic fatty liver disease is associated with higher levels of *objectively* measured sedentary behaviour and lower levels of physical activity than matched healthy controls. *Frontline Gastroenterol* 2015 Jan;6(1):44-51. doi:10.1136/flgastro-2014-100432. PMID: 25580206 (IF 7.896)
162. Manjunath V, Papastavrou V, Steel D, Menon G, Peto T, Taylor R, Talks J. Wide-field Imaging and OCT versus clinical evaluation of patients referred from Diabetic Retinopathy Screening. *Eye* 2015 Jan; 29: 416- doi:10.1038/eye.2014.320

163. Jakovljevic DG, Papakonstantinou L, Blamire AM, MacGowan GA, Taylor R, Hollingsworth KG, Trenell MI. Effect of Physical Activity on Age-Related Changes in Cardiac Function and Performance in Women. *Circ Cardiovasc Imaging*. 2015;8:e002086. doi:10.1161/CIRCIMAGING.114.002086. Epub 2014 Dec 30. PMID: 25550398 (IF 5.32)
164. Cassidy S, Hallsworth K, Thoma C, MacGowan GA, Hollingsworth KG, Day CP, Taylor R, Jakovljevic DG, Trenell MI. Cardiac structure and function are altered in Type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control. *Cardiovascular Diabetology* 2015 Feb 13;14:23. doi: 10.1186/s12933-015-0187-2. PMID: 25849783 (IF 6.671)
165. Steven S, Taylor, R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabet Med* 2015 32(9):1149-55. doi: 10.1111/dme.12722. PMID: 25683066 (IF 3.115)
166. Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Al-Mrabeh A, Schweizer A, Foley JE, Taylor R. Effect of Vildagliptin on Hepatic Steatosis. *J Clin Endocrinol Metab* 2015 Apr; 100(4):1578-85. doi: 10.1210/jc.2014-3794. Epub 2015 Feb 9. PMID: 25664602 (IF 6.209)
167. Madathil A, Hollingsworth KG, Blamire AM, Razvi S, Newton JL, Taylor R, Weaver JU. Levothyroxine Improves Abnormal Cardiac Bioenergetics in Subclinical Hypothyroidism: A Cardiac Magnetic Resonance Spectroscopic Study. *J Clin Endocrinol Metab* 2015 Apr. doi: 10.1210/jc.2014-2942. PMID: 25541742 (IF 6.209)
168. Macauley M, Smith FE, Thelwall PE, Hollingsworth KG, Taylor R. Diurnal variation in skeletal muscle and liver glycogen in humans with normal health and type 2 diabetes. *Clinical Science* 2015 May 1;128(10):707-13. doi: 10.1042/CS20140681. PMID: 25583442 (IF 5.598)
169. Macauley M, Percival K, Hollingsworth KG, Thelwall PE, Taylor R. Altered volume, morphology and composition of the pancreas in type 2 diabetes. *PLOS One* 2015 May 7;10(5):e0126825. doi: 10.1371/journal.pone.0126825. PMID: 25950180 (IF 3.234)
170. Mann LW, Higgins DM, Peters CN, Cassidy S, Hodson KK, Coombs A, Taylor R, Hollingsworth KG. Accelerating MR Imaging Liver Steatosis Measurement Using Combined Compressed Sensing and Parallel Imaging: A Quantitative Evaluation. *Radiology* 2016 Jan;278(1):247-56. doi:10.1148/radiol.2015150320. Epub 2015 Jul. PMID: 26218662 (IF 6.867)
171. Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B Al-Mrabeh AA, Daly AK, Batterham RL, Taylor R. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. *Diabetes Care* 2016 Jan;39(1):158-65. doi: 10.2337/dc15-0750. Epub 2015 Dec 1. PMID: 26628414 (IF 11.9)
172. Talks J, Manjunath V, Steel DHW, Peto T, Taylor R. New vessels detected on wide field imaging compared to 2-field and 7-field imaging: implications for diabetic retinopathy screening image analysis. *Br J Ophthalmol* 2015

Dec;99(12):1606-9. doi:10.1136/bjophthalmol-2015-306719. Epub 2015 Aug. PMID: 26271269 (IF 2.976)

173. Cassidy S, Thoma C, Hallsworth K, Parikh J, Hollingsworth KG, Taylor R, Jakovljevic DG, Trenell MI. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. *Diabetologia* 2016 Jan;59(1):56-66. doi: 10.1007/s00125-015-3741-2. Epub 2015 Sep. PMID: 26350611 (IF 6.671)
174. Gonzalez J, Fuchs C, Smith F, Thelwall P, Taylor R, Stevenson E, Trenell M, Cermak N, and van Loon L. Ingestion of Glucose or Sucrose Prevents Liver but not Muscle Glycogen Depletion During Prolonged Endurance-type Exercise in Trained Cyclists. *Am J Physiol Endocrinol Metab* 2015 Dec 15;309(12):E1032-9. doi:10.1152/ajpendo.00376.2015. PMID: 26487008 (IF 3.785)
175. Leslie WS, Ford I, Sattar N, Hollingsworth KG, Adamson A, Sniehotta FF, McCombie L, Brosnahan N, Ross H, Mathers JC, Peters C, Thom G, Barnes A, Kean S, McIlvenna Y, Rodrigues A, Rehackova L, Zhyzhneuskaya S, Taylor R, Lean ME. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. *BMC Family Practice* 2016 Feb 16;17:20. doi:10.1186/s12875-016-0406-2. <https://rdcu.be/6jwe> PMID: 26879684 (IF 1.67)
176. Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: Pathophysiologic changes in responders and nonresponders. *Diabetes Care* 2016 May 39(5):808-15. doi: 10.2337/dc15-1942. PMID: 27002059 (IF 11.9)
177. Al-Mrabeh A, Hollingsworth KG, Steven S, Taylor R. Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity. *Diabetologia* 2016 Aug;59(8):1753-9. doi: 10.1007/s00125-016-3984-6. Epub 2016 May 14. PMID: 27179658; <https://rdcu.be/3K5G> (IF 6.671)
178. Fuchs CJ, Gonzalez JT, Beelen M, Cermak NM, Smith FE, Thelwall PE, Taylor R, Trenell MI, Stevenson EJ, van Loon LJ. Sucrose ingestion after exhaustive exercise accelerates liver, but not muscle glycogen repletion compared with glucose ingestion in trained athletes. *J Appl Physiol* 2016 Jun 1;120(11):1328-34. doi: 10.1152/jappphysiol.01023.2015. Epub 2016 Mar 24. PMID: 27013608 (IF 3.838)
179. Avery L, Charman S, Taylor L, Flynn D, Mosely K, Speight J, Lievesley M, Taylor R, Sniehotta F, Trenell M. Systematic development of a theory-informed multifaceted behavioural intervention to increase physical activity of adults with type 2 diabetes in routine primary care: Movement as Medicine for Type 2 Diabetes. *Implementation Science* 2016 Jul 19;11:99. doi: 10.1186/s13012-016-0459-6. PMID: 27430648 (IF 3.201)
180. Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, McPherson S, Anstee QM, Trenell MI. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients with Non-alcoholic Steatohepatitis in a Randomized Controlled Trial. *Clin Gastroenterol*

Hepatol 2017 Jan;15(1):96-102.e3. doi: 10.1016/j.cgh.2016.07.031. Epub 2016 Aug 10. PMID: 27521509 (IF 7.896)

181. Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B, Al-Mrabeh A, Batterham RL, Taylor R. Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes. *Diabet Med* 2016 33:1723-31. doi: 10.1111/dme.13257. Epub ahead of print (IF 3.152)
182. Hodson K, Dalla Man C, Smith FE, Barnes A, McParlin C, Cobelli C, Robson SC, Araujo-Soares V, Taylor R. Liver triacylglycerol content and gestational diabetes: Effects of moderate energy restriction. *Diabetologia* 2017 Feb;60(2):306-313. doi: 10.1007/s00125-016-4143-9. PMID: 27817155 (IF 6.671)
183. Al-Mrabeh A, Hollingsworth KG, Steven S, Tiniakos D and Taylor R. Quantification of intrapancreatic fat in type 2 diabetes by MRI. *PLoS One* 2017 Apr 3;12(4):e0174660. doi: 10.1371/journal.pone.0174660. PMID: 28369092 (IF 3.234)
184. Houghton D, Hallsworth K, Thoma C, Cassidy S, Hardy T, Heaps S, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Trenell MI. Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. *Clin Gastroenterol Hepatol* 2017 May 10. pii: S1542-3565(17)30553-0. doi: 10.1016/j.cgh.2017.05.001. [Epub ahead of print]. PMID: 28501537 (IF 7.896)
185. Rehackova L, Araujo-Soares V, Adamson AJ, Steven S, Taylor R, Sniehotta F. F. Acceptability of a very-low-energy diet in Type 2 diabetes: patient experiences and behaviour regulation *Diabetic Med* 2017; 34: 1554–1567.
186. Taylor R, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson² AJ, Sniehotta FF, Mathers JM, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Lean MEJ. Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. *Diabetologia* 2017; 61:589-98
<https://doi.org/10.1007/s00125-017-4503-0> (IF 6.2)
187. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson² AJ, Sniehotta FF, Mathers JM, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care weight-management for type 2 diabetes: the cluster-randomised Diabetes Remission Clinical Trial (DiRECT). *Lancet* 2017; 391:541-51
doi.org/10.1016/S0140-6736(17)33102-1 (IF 44)
188. McParlin C, Hodson K, Barnes AC, Taylor R, Robson SC, Araujo-Soares V. Views, experience and adherence of pregnant women participating in a study of weight loss in gestational diabetes (WELLBABE). *Diabetic Medicine* 2019; 36:195-202. doi: 10.1111/dme.13788

189. Taylor R, Barnes AC. Translating aetiological insight into sustainable management into type 2 diabetes. *Diabetologia* 2018; 61: 273-283 doi: 10.1007/s00125-017-4504
190. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes A, Aribisala B, Hollingsworth KG, Mathers JC, Sattar N, Lean MEJ. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery. *Cell Metab.* 2018 Oct 2;28(4):547-556.e3. doi: 10.1016/j.cmet.2018.07.003.
191. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JM, Ross HM, McIlvenna Y, Welsh, P, Kean, S, Ford I, McConnachie A, Messow, C-M Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet* 2019; 7: 344–55; doi:10.1016/s2213-8587(19)30068-3.
192. Xin Y, Davies A, McCombie L, Briggs A, Messow, C-M, Grieve E, Leslie WS, Taylor R, Lean MEJ. Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial. *Diabetic Med* 2019. April 26 doi:10.1111/dme.13981.
193. Rehackova L, Araujo-Soares V, Steven S, Adamson AJ, Taylor R, Sniehotta FF. Behaviour change during dietary type 2 diabetes remission: A longitudinal qualitative evaluation of an intervention using a very low energy diet. *Diabetic Med* 2020 June;37(6):953-962. doi: 10.1111/dme.14066. Epub 2019 Aug 8.
194. Bynoe K, Unwin N, Taylor C, Murphy M, Greenidge A, Abed M, Jeyaseelan S, Cobelli C, Dalla Man C, Taylor R. Inducing remission of Type 2 diabetes in the Caribbean: findings from a mixed methods feasibility study of a low-calorie liquid diet-based intervention in Barbados. *Diabetic Med* 2019; July 31 doi:10.1111/dme.14096
195. Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, Barnes AC, Melhem S, Jesuthasan A, Aribisala B, Hollingsworth KG, Lietz G, Mather JC, Sattar N, Lean MEJ, Taylor R. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. *Cell Metabolism* 2020 Feb 4;31(2):233-249.e4. doi: 10.1016/j.cmet.2019.11.018
196. Zhyzhneuskaya SV, Al-Mrabeh A, Peters C, Barnes AC, Aribasala B, Hollingsworth KG, McConnachie A, Sattar N, Lean MEJ, Taylor R. Time course of normalisation of functional beta cell capacity in DiRECT after weight loss in type 2 diabetes. *Diabetes Care* 2020; 43(4): 813-820; doi: 10.2337/dc19-0371.

197. Preshaw PM, Taylor JJ, Jaedicke KM, De Jager M, Bikker JW, Selten W, Bissett SM, Whall KM, Van de Merwe R, Areibi A, Jitprasertwong P, Al-Shahwani R, Weaver J, Taylor R, Wassall RR. Treatment of periodontitis reduces systemic inflammation in type 2 diabetes. *Journal of Clinical Periodontology* 2020; February 27; doi: 10.1111/jcpe.13274.
198. Kusinski LC, Murphy HR, De Lucia Rolfe E, Rennie KL, Oude Griep LM, Hughes D, Taylor R, Meek CL. Dietary Intervention in pregnant women with gestational diabetes; protocol for the DiGest randomised controlled trial. *Nutrients* 2020; April 22; doi: 10.3390/nu12041165.
199. Yiqiao X, Davies A, Briggs A, McCombie L, Messow C-M, Grieve E, Leslie WM, Taylor R, Lean MEJ. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. *Diabetologia* 2020; 63(10):2112-2122 DOI: 10.1007/s00125-020-05220-6;
200. Thom G, McIntosh A, Messow C-M, Leslie WS, Barnes A, Brosnahan N, McCombie L, Malkova D, Al-Mrabeh A, Zhyzhneuskaya S, Welsh P, Sattar N, Taylor R, Lean MEJ. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). *Diabetes Obes Metab* 2020; DOI: 10.1111/dom.14274
201. Al-Mrabeh A, Hollingsworth KG, Shaw JAM, McConnachie A, Sattar N; Lean MEJ, Taylor R. 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2020; 8: 939-948; doi: 10.1016/S2213-8587(20)30303-X
202. Al-Mrabeh A, Peters C, Hollingsworth KG, Taylor R. Measurement of intraorgan fat and hepatic output of triglycerides in human type 2 diabetes by magnetic resonance and intralipid infusion techniques. *Star Protocols* 2021; 2:1 <https://doi.org/10.1016/j.xpro.2021.100355>
203. Brosnahan N, Leslie W, McCombie L, Barnes A, Thom G, McConnachie A, Messow C M, Sattar N, Taylor R, Lean M E J. Brief formula low-energy-diet for relapse management during weight loss maintenance in the Diabetes Remission Clinical Trial (DiRECT). *J Hum Nutr Diet.* 2021;00:1-8 <https://doi.org/10.1111/jhn.12839>
204. Thom G, Messow C-M, Leslie WS, Barnes AC, Brosnahan N, McCombie EL, Al-Mrabeh A, Zhyzhneuskaya S, Welsh P, Sattar N, Taylor R, Lean MEJ. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabetic Medicine* 2020 <https://doi.org/10.1111/dme.14395>

205. Shaden M, Steven S, Taylor R, Al-MrabeH A. Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study. *Nutrients* 2021, 13(5), 1465 doi: 10.3390/nu13051465
206. Rehackova L, Rodrigues AM, Thom G, Brosnahan N, Barnes AC, McCombie L, Leslie WS, Zhyzhneuskaya S, Peters C, Adamson AJ, Lean MEJ, Taylor R, Sniehotta FF. Participant experiences in the Diabetes REmission Clinical Trial (DiRECT). *Diabet Med* 2021;00:e14689 <https://doi.org/10.1111/dme.14689>
207. Leslie WS, Ali E, Harris L, Martina Messow C, Brosnahan NT, Thom G, McCombie EL, Barnes AC, Sattar N, Taylor R, Lean MEJ. Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes REmission Clinical Trial (DiRECT). *Diabetologia* (2021) 64:1927–1938 <https://doi.org/10.1007/s00125-021-05471-x>
208. Jesuthasan A, Zhyzhneuskaya S, Peters C, Barnes AC, Hollingsworth KG, Sattar N, Lean MEJ, Taylor R, Al-MrabeH AH. Sex differences in intraorgan fat levels and hepatic lipid metabolism: implications for cardiovascular health and remission of type 2 diabetes after dietary weight loss. *Diabetologia* 2022; 65(1): 226–233 <https://doi.org/10.1007/s00125-021-05583-4>
209. Rehackova L, Rodrigues AM, Thom G, Brosnahan N, Barnes AC, McCombie L, Leslie WS, Zhyzhneuskaya S, Peters C, Adamson AJ, Lean MEJ, Taylor R, Sniehotta FF. Delivering the Diabetes Remission Clinical Trial (DiRECT) in primary care: A mixed-methods study of experiences of health care professionals. *Diabet Med* 2022; 39:e14952; DOI: [10.1111/dme.14752](https://doi.org/10.1111/dme.14752)
210. Kusinski LC., Murphy HR., Jones D. L., Brown J., Turner E., Hughes D. J., Dyson P., Ahern A., Taylor R., Meek C. Dietary Intervention in Pregnant Women with Gestational Diabetes; Protocol for the DiGest Randomised Controlled Trial. *Nutrients* 2020, 12, 1165-77
211. Williams SA, Rachel Ostroff, Michael A. Hinterberg, Josef Coresh, Christie M. Ballantyne, Matsushita K, Mueller CE, Walter J, Jonasson C, Holman RR, Shah SH, Sattar N, Taylor R, Michael Lean, Shintaro Kato, Hiroaki Shimokawa, Yasuhiko Sakata, Kotaro Nochioka, C Parikh, Steven Coca, Torbjørn Omland, Jessica Chadwick, David Astling, Yolanda Hagar, Natasha Kureshi, Kelsey Loupy, Clare Paterson, Jeremy Primus, Missy Simpson, Nelson P. Trujillo, Peter Ganz. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. *Science Translational Reports* 2022, 14, eabj9625.
212. Cassidy S, Trenell M, Stefanetti RJ, Charman SJ, Barnes AC, Brosnahan N, McCombie L, Thom G, Peters C, Zhyzhneuskaya S, Leslie WS, Catt C, Catt M, McConnachie A, Sattar N, Sniehotta FF, Lean MEJ, Taylor R. Physical activity, inactivity and sleep during the Diabetes Remission Clinical Trial (DiRECT). *Diabetic Medicine* 2022 40:e15010. doi: 10.1111/dme.15010
213. Unwin D, Delon C, Unwin J, Tobin S, Taylor R. What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a

214. Sattar N, Taheri S, Astling DP, Chadwick J, Hinterberg MA, Holmes MV, Troth EV, Welsh P, Zaghoul H, Chagoury O, Lean M, Taylor R, Williams S. Prediction of cardiometabolic health through changes in plasma proteins with intentional weight loss in the DiRECT and DIADEM-I randomised clinical trials of type 2 diabetes remission. *Diabetes Care* 2023; 46:1949-57. doi: 10.2337/dc23-0602. Online ahead of print.
215. Goudswaard LJ, Smith ML, Hughes DA, Taylor R, Lean M, Sattar N, Welsh P, McConnachie A, Blazeby JM, Rogers C, Suhre K, Zaghool SB, Hers I, Timpson NJ & Corbin LJ. Using trials of caloric restriction and bariatric surgery to explore the effects of body mass index on the circulating proteome. *Scientific Reports* 2023; 13:21077
https://www.researchgate.net/publication/376044260_Using_trials_of_caloric_restriction_and_bariatric_surgery_to_explore_the_effects_of_body_mass_index_on_the_circulating_proteome.
216. Corbin LJ, Hughes DA, Bull CJ, Vincent EE, Smith ML, McConnachie A, Messow C, Welsh P, Taylor R, Lean MEJ, Sattar N, Timpson NJ. The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabetologia* 2024; 67:74–87
<https://doi.org/10.1007/s00125-023-06019-x>
217. Taylor R, Barnes AC, Hollingsworth KG, Irvine KM, Solovyova A, Clark L, Martin-Ruiz C, Romeres R, Koulman A, Meek CM, Jenkins B, Cobelli C, Holman R. Aetiology of Type 2 diabetes in people with a ‘normal’ body mass index: testing the personal fat threshold hypothesis. *Clin Sci (Lond)* (2023) 137: 1333–1346
doi.org/10.1042/CS20230586
218. Caroline J. Bull CJ, Hazelwood E, Legge DN, Corbin LJ, Richardson TG, et al, Taylor R, Lean MEJ, Sattar N, Murphy N, Gunter MJ, Timpson NJ, Vincent EE³. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised-controlled trial of individuals with type 2 diabetes Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised-controlled trial of individuals with type 2 diabetes. *eBioMedicine* 2024; 100: 104977 <https://doi.org/10.1016/j.ebiom.2024.104977>
219. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Kelly T, Irvine K, Peters C, Zhyzhneuskaya S, Hollingsworth KG, Adamson AA, Snihotta FF, Mathers JC, McIlvenna Y, Welsh P, McConnachie A, McIntosh A, Sattar N, Taylor R. Five-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT): Extension study of continued support for weight loss maintenance. *Lancet Diabetes & Endocrinol.* 2024; 12:233-246
[https://doi.org/10.1016/S2213-8587\(23\)00385-6](https://doi.org/10.1016/S2213-8587(23)00385-6)
220. Valabhji J, Gorton Y, Barron E, Safazadeh S, Earnshaw F, Helm C, Virr M, Kernan J, Crowe S, Aveyard P, Wilding J, Willis T, Ells L, O’Neill S, Robertson

- E, Jebb S, Taylor R, Bakhai C. Early findings from the NHS Type 2 Diabetes Path to Remission Programme. *Lancet Diabetes and Endocrinology* 2024; 12:653-63. [https://doi.org/10.1016/S2213-8587\(24\)00194-3](https://doi.org/10.1016/S2213-8587(24)00194-3)
221. Zhyzhneuskaya SV, Al-Mrabeh A, Peters C, Barnes AC, Aribasala B, Hollingsworth KG, McConnachie A, Sattar N, Lean MEJ, Taylor R. Clinical utility of liver function tests for resolution of metabolic dysfunction-associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial. *Diabetic Medicine* 2025;e15462 <https://doi.org/10.1111/dme.15462>
222. Kusinski LC, Jones DL, Atta N, Turner E, Smith S, Oude Griep L, Rennie K, De Rolfe Lucia L, Sharp S, Farewell V, Murphy M, Taylor R, Meek CL. Reduced energy diet in women with gestational diabetes: the dietary intervention in gestational diabetes (DiGest) trial. *Nature Medicine* 2025 31: 514-523 <https://doi.org/10.1038/s41591-024-03356-1>
223. Kusinski LC, Atta N, Jones DL, Smith S, Cooper L, Oude Griep LM, Rennie K, De Lucia Rolfe E, Murphy HR, Scott EM, Sharp SJ, Taylor R, Meek CL. Continuous glucose monitoring metrics and pregnancy outcomes in women with gestational diabetes: results from the DiGest trial. *Diabetes Care* 2025 doi: 10.2337/dc25-0452 Online ahead of print
224. Dib S, Kusinski LC, Jones DL, Atta N, Smith S, De Lucia Rolfe E, Murphy HR, Taylor R, Meek CL. Energy Restriction, Weight Loss, Glycemia, and Breastfeeding Outcomes in Gestational Diabetes: A DiGest Trial Secondary Analysis. *Diabetes Care* 2025 <https://doi.org/10.2337/dc24-2625>
225. Epstein B, Chadwick J, Carpenter MA, Williams SA, ... Taylor R, Paterson C. A proteomic tool suggests reductions in dementia risk following intentional weight loss in type 2 diabetes. *Alzheimer's Dement.* 2025;21(Suppl. 7):e108444.
226. Davies A, Grieve E, McCombie L, McIntosh A, McConnachie A, Leslie WS, Sattar N², Taylor R, Lean MEJ. Cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow up. *Diabetic Medicine* 2026 In press
227. Dib S, Kusinski LC, Luo N, Jones DL, Smith S, Murphy HR, Taylor R, Meek CL. The association between early diagnosis of gestational diabetes and maternal-neonatal outcomes: a secondary analysis of the DiGest trial. *Endocrine* 2026; in press

Reviews, Editorials and Book Chapters

- R1. Johnston DG, Taylor R, Alberti KGMM, Whittaker J, Faber O, Binder C, Hammond V. Insulin secretion and action in liver disease. In *Recent Advances in Obesity and Diabetes Research*, N Melchionda, D Horwitz, DS Schade (Ed.) Academic Press 1984; London p. 117-127
- R2. Taylor R. Insulin receptor assays - Clinical application and limitation. *Diabetic Medicine* 1984; 1: 179-184
- R3. Alberti KGMM, Johnston DG, Taylor R. Carbohydrate metabolism in liver disease. In *Liver and Biliary Disease* 1984; (Ed R Wright) WB Saunders, 44-69
- R4. Taylor R, Johnston DG, Alberti KGMM. Glucose homeostasis in chronic liver disease. *Clinical Science* 1986; 70:317-320
- R5. Taylor R. Jet injection of insulin. *Lancet* 1985; i: 1140 (Editorial)
- R6. Taylor R. Insulin receptors and the clinician. *British Medical Journal* 1986; 292: 919-922
- R7. Johnston DG, Taylor R, Alberti KGMM. Mechanisms of endocrine abnormalities in liver cirrhosis. In *Cirrhosis of the liver: Methods and fields of research* 1989; (Ed F Orlands and N Tygstrup) Academic Press
- R8. Taylor R, Home PD. Management of insulin resistance. In *Diabetes: Clinical Management* 1990; (Ed. Tattersall R and Gale E) Churchill Livingstone, p. 245-249
- R9. Abu-Bakare A, Taylor R, Gill GV, Alberti KGMM. Tropical diabetes: Does it exist? *Lancet* 1986; i: 1135-1138.
- R10. Taylor R. Drugs and Glucose Tolerance. *Adverse Drugs Reaction Bull*, 1986, 121:452-455. Reprinted by publishers in *Medicine Digest*, 1988; 14:15-19
- R11. Kruszynska YT, Home PD, Petranyi G, Taylor R, Alberti KGMM. Skeletal muscle metabolism and blood intermediary metabolite concentrations in insulin treated diabetes. In *Advanced models for the therapy of insulin dependent diabetes* 1987; Ed. Brunetti P, Waldhaus WK. Raven Press, NY, p 53-57.
- R12. Taylor R. Metabolic studies on adipose tissue. In: *Bailliere's Clinical Endocrinology and Metabolis* 1987; Ed. Alberti KGMM, Home PD, Taylor R. WB Saunders, p.1023-1037
- R13. Alberti KGMM, Home PD, Taylor R. Eds. *Bailliere's Clinical Endocrinology & Metabolism* 1987; WB Saunders.
- R14. Taylor R, Agius L. The biochemistry of diabetes. *Biochemical Journal* 1988; 250:625-640
- R15. Alberti KGMM, Boucher BJ, Hitman GA, Taylor. Diabetes. In: *The Metabolic Basis of Acquired Disease* 1990. Bailliere Tindall, p. 765-840
- R16. Taylor R. Insulin for the non-insulin dependent? *British Medical Journal* 1988; 296:1015-1016

- R17. Taylor R. Insulin: Delivery to the right place at the right time. In *Current Medicine* 1988; Ed AD Toft, Gower Academic Journals p. 29-33
- R18. Taylor R. Aetiology of non-insulin dependent diabetes. *British Medical Bulletin* 1989; 45:73-91
- R19. Taylor R. Non-insulin dependent diabetes: No longer the poor cousin. *Proceedings of Royal College of Physicians of Edinburgh* 1989; 19:183-190
- R20. Taylor R. Postgraduate training and/or education? *Diabetic Medicine* 1989; 6:655-656
- R21. Alberti KGMM, Taylor R. The aetiology of type II diabetes. In *Non-insulin Dependent Diabetes*. Elsevier 1989; Excerpta Medica, p. 35-43
- R22. Taylor R. Insulin treatment in NIDDM: When, Why & How. Royal Society of Medicine, Current Medical Literature *Diabetes* 1989; 6:91-94
- R23. Taylor R. Drug interactions in diabetes. In *Textbook of Diabetes*. Ed. Pickup J and Williams G. Blackwell 1991; p. 803-812
- R24. Taylor R. Insulin action 1991. *Clinical Endocrinology* 1991; 34:159-171
- R25. Taylor R & Johnson AB. Annual Review - Diabetes Mellitus. *Postgraduate Medical Journal* 1990; 66:1010-1024
- R26. Alberti KGMM, Johnston DG, Taylor R. Carbohydrate metabolism in liver disease. In *Liver and Biliary Disease* 1991; 3rd edition (Ed R Wright) WB Saunders, p. 43-60
- R27. Alberti KGMM, Jones IR, Laker MF, Swai ABM, Taylor R. Effect of bezafibrate on metabolic profiles in NIDDM. *Journal of Cardiovascular Pharmacology* 1990; 16: (Suppl 9) 521-525
- R28. Broughton DL, Taylor R. Deterioration of glucose tolerance with age: The role of insulin resistance. *Age and Ageing* 1991; 20:221-225
- R29. Taylor R. Resistance to injection. *Diabetic Medicine* 1992; 9:104-108
- R30. Taylor R. Metabolic abnormalities in the polycystic ovary syndrome. *Clinical Endocrinology* 1992; 36:535-536
- R31. Taylor R. Use of insulin in non-insulin dependent diabetes. *Diabetes Reviews* 1:9-11, 1992
- R32. Alberti KGMM, Johnson AB, Taylor R. Gliclazide: metabolic and vascular effects - a metabolic perspective. *Metabolism* 1992; 41 (Suppl 1):40-45
- R33. Taylor R. Management of non-insulin dependent diabetes. *Eye* 1993; 7:298-301, 1
- R34. Stewart M, Taylor R. Gestational Diabetes. *Diabetic Nursing* 1993; 3:6-8
- R35. Gregory J, Taylor R. Carbohydrate metabolism in childhood diabetes. In *Diseases of Childhood* 1994; Ed CJH Kelnar. Chapman & Hall, p. 191-212
- R36. Hurel S, Taylor R. Adverse effects of drugs on blood glucose control. *Diabetes in General Practice* 1993.

- R37. Taylor R, Vanderpump M. New concepts in diabetes mellitus I: Treatment, pregnancy & aetiology. *Postgraduate Medical Journal* 1994; 70:418-427
- R38. Vanderpump M, Taylor R. New concepts in diabetes mellitus II: Complications. *Postgraduate Medical Journal* 1994; 70:479-485
- R39. Taylor R. Insulin resistance and the dynamics of NIDDM. *Diabetes International Developments in Diagnosis and Therapy* 1994; 15:4-7
- R40. Taylor R, Shulman GI. New insights into carbohydrate metabolism in man by application of *in vivo* magnetic resonance spectroscopy. *Diabetes Annual* 1994; 8:157-175
- R41. Robertson D, Taylor R. Metabolic causes of syncope. In *Syncope in the elderly* 1995; Ed RA Kenny. Chapman & Hall
- R42. Hurel S, Taylor R. Drugs and Hyperglycaemia. *Adverse Drugs Reaction Bulletin* 1996
- R43. Johnson AB, Taylor R. Acarbose. *Prescribers' Journal* 1996; 36:169-172
- R44. Leslie RDG, Taylor R, Pozzilli P. The role of insulin resistance in the natural history of type I diabetes. *Diabetic Medicine* 1996; 14:327-331
- R45. Taylor R, Shulman GI. Recent advances in carbohydrate metabolism. In *Clinical Diabetes Research* 1997; Part 1. Ed B Drasnin & RA Rizza Humana Press, Chapter 14, p. 287-303
- R46. Taylor R, Lovelock L, Ryder R. *A Practical Guide To Polaroid Retinal Screening* 1996; Moseby Wolfe Book]
- R47. Taylor R. Insulin resistance: Circumventing Nature's blocks. *Lancet* 1996; 348:1045-1046
- R48. Taylor R. Measuring insulin resistance in diabetes. *Diabetes News* 1997; 18(2):6-8
- R49. Taylor R, Koay P, Cottrell D, Stannard KS. Diabetic retinopathy: A dynamic approach. Moseby Wolfe 1998 [CD-Rom]
- R50. Taylor R, Broadbent DM, Greenwood R, Hepburn D, Owens DR, Simpson H. Mobile retinal screening in Britain. *Diabetic Medicine* 1998; 15:344-347
- R51. Taylor R. The Nature of Type 2 diabetes. *Proceedings of the Eighth NovoNordisk Diabetes Update* 1999; p 3-9
- R52. Taylor R. Diabetes and eye disease. *Medicographia* 1999; 21:342-345
- R53. Taylor R. The nature of Type 2 diabetes: the role for new agents. *International Journal of Clinical Practice* 1999; p. 14-17
- R54. Taylor R, Shulman GI. Regulation of hepatic glucose uptake. *Handbook of Physiology* 2nd edition: The Endocrine Pancreas and Regulation of Metabolism. Ed LS Jefferson and AD Cherrington. 2001; 787-802
- R55. Taylor R, Marsden PJ. Insulin sensitivity and fertility. *Human Fertility* 2000; 3: 65-69

- R56. Taylor R. How large studies may mislead: the HOPE study. *Practical Diabetes* 2001; 18:208-211
- R57. Arun CS, Taylor R. Diabetic retinopathy. *Diabetes Voice* 2003
- R58. Ravikumar B, Taylor R. Insulin resistance in type 1 diabetes. In *Unstable Diabetes* 2003; Ed GV Gill
- R59. Dashora U, Taylor R. Maintaining tight glycaemic control during intermittent high dose Prednisolone administration during type 1 diabetic pregnancy. In *Fifty cases of Diabetes* Ed DJ Betteridge Martin Dunitz, London & New York, 2003; 17-20
- R60. Taylor R, Shulman GI. Magnetic resonance spectroscopy studies of liver and muscle glycogen metabolism in humans. *Joslin Textbook of Diabetes* Ed R Kahn 2004
- R61. Taylor R. Causation of type 2 diabetes – The Gordian knot unravels. *New England Journal of Medicine* 2004; 350: 639-641. PMID: 14960738 (IF 55.873)
- R62. Al-Bermani A, Taylor R. Screening for diabetic retinopathy. In *Diabetes Screening* Ed M Ganz, Wiley, London 2004
- R63. Taylor R. Diabetes. In *50 Case Studies in Cardiology* Ed Julian D. Science Press Internet Services Ltd, London 2004
- R64. Taylor R. Postgraduate training and/or education? *Diabetic Medicine* 6:655-656; 1989
- R65. Taylor R Vision in Diabetes: The 2005 Arnold Bloom Lecture. *Practical Diabetes* 2005; 22: 266-271
- R66. Taylor R. Handbook of Retinal Screening in Diabetes. *Wiley London* 2006 (associated website www.servier.co.uk/retinalimagebank)
- R67. Al-Bermani A, Taylor R. Techniques for the investigation of the eye in diabetes. In *Clinical Research in Diabetes and Metabolism: Methods and Techniques*. Wiley, London 2007; 357-366
- R68. Taylor R. Digami too? *Diabetologia* 2006; 49:1134-7. PMID: 16609878
- R69. Taylor R, Davison JM. Type 1 diabetes and pregnancy. *BMJ*. 2007; Apr 7;334(7596):742-5. PMID: 17413175
- R70. Taylor R. Islet cell function: The onset and progression of type 2 diabetes. *US Endocrine Disease* 2006; Issue 2, 53-55
- R71. Al-Bermani A, Taylor R. Treatment of diabetic retinopathy. Evidence Based Diabetes. Ed WH Herman, AL Kinmonth, NJ Wareham, R Williams. Wiley, London 2010, 275-284
- R72. Taylor R. The PROactive and DREAM studies. *US Endocrine Disease* 2006; Issue 2, 91-92
- R73. Taylor R. Pathogenesis of Type 2 Diabetes: Tracing the reverse path from cure to cause. *Diabetologia* 2008; 51:1781-1789. PMID: 18726585

- R74. Al-Bermani A, Taylor R. Techniques for investigation of the eye in diabetes. *Clinical Diabetes Research: Methods and Techniques 2009*; Ed M Roden. Wiley, London
- R75. Lim EL, Taylor R. Clinical Presentations of Diabetes. In *Textbook of Diabetes 4th Edition*. Ed R Holt, B Goldstein, A Flyvbjerg, C Cockram. Wiley-Blackwell, London. 2010
- R76. Taylor R. Balancing fear of hypoglycaemia with optimal control in pregnancy. HbA1c in Diabetes. Ed S Gough, S Manley, I Stratton. Wiley-Blackwell, 2010
- R77. Hodson K, Robson S, Taylor R. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*. 2010; 3:128-132. doi: 10.1258/om.2010.100025
- R78. Taylor R, Steven S. Pathophysiology of Type 2 Diabetes. In *Type 2 Diabetes* Ed AH Barnett. Oxford University Press 2012
- R79. Taylor R, Batey D. *Handbook of Retinal Screening in Diabetes*. 2nd Edition. Wiley 2012
- R80. Preshaw PM, Alba AL, Herrer D, Jepsen S, Konstantinidis, Makrilakis K, Taylor R. Periodontitis and diabetes: a two-way relationship. *Diabetologia*. 2012; 55:21-31
- R81. Taylor R. Reversing Type 2 diabetes. *Practical Diabetes* 2011; 28: 377-378
- R82. Taylor R. Insulin resistance and type 2 diabetes. *Diabetes* 2012 Apr; 61(4):778-9. doi: 10.2337/db12-0073. PMID: 22442298 (IF 8.095)
- R83. Knop F, Taylor R. Mechanism of metabolic advantage after bariatric surgery - *it's all gastrointestinal factors vs. it's all food restriction*. *Diabetes Care* 2013 Aug; 36 S2:S287-291; doi: 10.2337/dcS13-2032. PMID: 23882061 (IF 11.9)
- R84. Taylor R. Reversing the Twin Cycles of Type 2 Diabetes: The Banting Lecture 2012. *Diabetic Medicine* 2013; 267-275. PMID: 23075228 (IF 3.115)
- R85. Taylor R. Type 2 Diabetes: Etiology and Reversibility. *Diabetes Care*, April 2013; 36(4):1047-105; doi: 10.2337/dc12-1805. PMID: 23520370 (IF 11.9)
- R86. Taylor R. Things that go bump in the night. *Diabetic Medicine* 2013, 30:889-90. doi: 10.1111/dme.12183
- R87. Taylor, R. Effective Management of Severe Vomiting in Pregnancy. *Physician* 2013 Jun; 2(1)
- R88. Peters C, Steven S, Taylor R. Reversal of Type 2 Diabetes by Weight Loss Despite Presence of Macro- and Microvascular Complications. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association, 2015, p. 271-274
- R89. Peters C, Taylor R. Pregnancy effect on diabetic gastroparesis. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association, 2015, p. 378-380

- R90. Taylor R, Holman R. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. *Clinical Science* 2015 Apr;128(7):405-410. doi: 10.1042/CS20140553 PMID: 25515001 (IF 5.598)
- R91. Rehackova L, Arnott B, Araujo-Soares V, Adamson AA, Taylor R, Sniehotta FF. Efficacy and Acceptability of Very Low Energy Diets in Overweight and Obese People with Type 2 Diabetes Mellitus: A Systematic Review with Meta-analysis. *Diabetic Medicine* 2016; 33:580-9. doi 10.1111/dme.13005
- R92. White MG, Shaw JAM, Taylor R. Type 2 diabetes: The pathologic basis of reversible beta-cell dysfunction. *Diabetes Care* 2016; 39:2080-88. doi 10.2337/dc16-0619
- R93. Taylor R. Calorie restriction and Reversal of Type 2 diabetes. *Expert Reviews in Diabetes and Metabolism* 2016 Volume 11, Issue 6, p521-528; <http://www.tandfonline.com/doi/full/10.1080/17446651.2016.1239525>
- R94. Leslie WS, Taylor R, Harris L, Lean M. Weight losses with low energy formula diets in obese patients with and without type 2 diabetes: Systematic review and meta-analysis. *Int J Obes (Lond)*. 2017; 41:96-101. doi: 10.1038/ijo.2016.175 (IF 5.337)
- R95. Zhzhysneuskaya S and Taylor R. Obesity and Type 2 Diabetes. In *Obesity. Pathogenesis, Diagnosis, and Treatment* edited by Paolo Sbraccia and Nicholas Finer. Springer 2017
- R96. Taylor R, Barnes A. Translating aetiological insight into sustainable management of type 2 diabetes? *Diabetologia* 2017; 61:273-83 doi: 10.1007/s00125-017-4504-z (IF 6.2)
- R97. Taylor R. Putting insulin resistance into context by dietary reversal of type 2 diabetes. *J R Coll Physicians (Edinb)*. 2017; 47:168-71. doi: 10.4997/JRCPE.2017.216
- R98. McCombie L, Leslie W, Taylor R, Kennon B, Sattar N, Lean MEJ. Beating type 2 diabetes into remission. *Brit Med J* 2017; 358:j4030. doi 10.1136/BMJ.j4030 (IF 20.8)
- R99. Forouhi N, Misra A, Mohan V, Taylor R, Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. *Brit Med J* 2018;361:Suppl p. 28-35
- R100. Taylor R, Barnes A. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. *Diabetic Medicine* 2018; 00:1-8 (2018) doi: 10.1111/dme.13851
- R101. Taylor, R, Valabhji,J, Aveyard P, Paul,D. Prevention and reversal of Type 2 diabetes: highlights from a symposium at the 2019 Diabetes UK Annual Professional Conference. *Diabetic Medicine* 2018; 00:1-7 (2019) doi: 10.1111/dme.13892

- R102. Taylor, R. Calorie restriction for long-term remission of type 2 diabetes. *Clinical Medicine* 2019 Vol 19, No 1:37-42
- R103. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes and Endocrinol.* 2019; 7:726-736. doi: 10.1016/S2213-8587(19)30076-2
- R104. Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. *Journal of Internal Medicine* 2021; 289: 754–770
<http://dx.doi.org/10.1111/joim.13214>
- R105. Taylor R. Remission of type 2 diabetes – Latest Information for Health care Professionals. *Practical Diabetes* 2020 37:177-182
- R106. Taylor R, Ramachandran A, Yancy Jr WS, Forouhi NG. Nutritional basis of type 2 diabetes remission. *Brit Med J* 2021; 373: n1449.
- R107. Petrov M, Taylor R. Intra-pancreatic fat deposition: Piecing the exocrine and endocrine pancreas together. *Nature Reviews Gastroenterology & Hepatology* 2021 online <https://doi.org/10.1038/s41575-021-00551-0>. [View only <https://rdcu.be/cCQzO>]
- R108. Singh M, Hung ES, Cullum A, Allen RE, Aggett PJ, Dyson P, Forouhi NG, Greenwood DC, Pryke R, Taylor R, Twenefour D, Waxman R, Young IS, Lower carbohydrate diets for adults with type 2 diabetes. *Diabetic Medicine* 2021;00:e14674. doi: 10.1111/dme.14674
- R109. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. *Diabetes Care* 2021;44(10):2438–2444
<https://doi.org/10.2337/dci21-0034>
- R110. Darke P, Cassidy, S, Catt M, Taylor R, Missier P, Bacardit J. Curating a longitudinal research resource using linked primary care EHR data—a UK Biobank case study. *Journal of the American Medical Informatics Association* 2021; 29(6) DOI: [10.1093/jamia/ocab260](https://doi.org/10.1093/jamia/ocab260)
- R111. Taylor R. Philip Home – Insulin, Insight and Internationalism. *Diabetes Care* 2022;45:497-501 DOI: 10.2337/dci21-0068
- R112. Taylor R. Type 2 Diabetes: The Problem and the Solution. *Br J Diabetes* 2022;22(Supp1):S55-S58 <https://bjd-abcd.com/index.php/bjd/article/view/1055/1307>
- R113. Taylor R. Very Low Calorie and Total Diet Replacement Diets in type 2 diabetes: where are we now? *Drug and Therapeutics Bulletin* 2024: DOI: [10.1136/dtb.2022.000055](https://doi.org/10.1136/dtb.2022.000055)

- R114. Manley S, Mostafa S, Webber J, Ganapathay KD, Taylor R, Little RR, Raghavan RP, Webster C, Barrat, A, Round RR, Stratton IM, Karwath A, Williams JA, Gkoutos GV, Roberts GA, Ghosh S. When is HbA1c useful and what do the numbers mean – do they help or hinder? *British Journal of Diabetes* 2023; 23:105-113 DOI: [10.15277/bjd.2023.417](https://doi.org/10.15277/bjd.2023.417)
- R115. Thirunavukkarasu S, Taylor R, Khunti K, Tapp RJ, Raben A, Zhu R, Kapoor N, Narayan KMV, Ali MK & Shaw JE. Low-calorie diets for people with Isolated impaired fasting glucose. *Communications Medicine* 2024; 4:35 <https://doi.org/10.1038/s43856-024-00466-2>
- R116. Taylor R. Understanding the cause of type 2 diabetes. *Lancet Diabetes & Endocrinology* 2024; 12:664-73 [https://doi.org/10.1016/S2213-8587\(24\)00157-8](https://doi.org/10.1016/S2213-8587(24)00157-8)
- R117. Taylor R. Is lasting remission feasible in the real-world setting? Yes! *Br J Diabetes* 2024;24(1):95-96 <https://doi.org/10.15277/bjd.2024.450>
- R118. Taylor R. The Twin Cycle Hypothesis of type 2 diabetes aetiology: From concept to national NHS programme. *Experimental Physiology* 2025; 110: 984-991 <https://doi.org/10.1113/EP092009>
- R119. Taylor R. The 2024 Claude Bernard Lecture: The aetiology of type 2 diabetes – an experimental medicine odyssey. *Diabetologia* 2025; 68:1375–1389 <https://doi.org/10.1007/s00125-025-06428-0>
- R120. Vujasinovic M, Demir IE, Marchegiani G, others, Taylor R et al. International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG. *United European Gastroenterology Journal*, 2026; 14:e70185 1 of 31 <https://doi.org/10.1002/ueg2.70185>

Short Commentaries

(1997 onwards)

- C1. Taylor R. Attempt to characterise the cellular defects of insulin action in NIDDM. *International Diabetes Monitor* 6:9-10, 1997
- C2. Taylor R. Alternatives to the retinal camera. *Diabetic Medicine* 1997; 14:622
- C3. Taylor R. Book review: How to write a paper. *Journal of the Royal College of Physicians* 1999
- C4. Taylor R. Dose-response study of a novel insulinotropic agent BTS 67 582 in Type 2 diabetes. *International Diabetes Monitor* 10:13, 1998
- C5. Taylor R. Muscle Rad expression and human metabolism. *International Diabetes Monitor* 10:15-16, 1998
- C6. Taylor R. Molecular mechanisms of insulin resistance. *Experimental and Clinical Endocrinology and Diabetes* 107:111-112, 1999

- C7. Taylor R. Is TNF α relevant to type 2 diabetes? *International Diabetes Monitor* 11:9-11, 1999
- C8. Taylor R. Faulty conclusions from study of conventional and intensive glucose control in pregnancy: Response to Nachum et al *BMJ* 6.11.99. *Brit Med J letter*: <http://www.bmj.com/cgi/eletters?lookup> 23 November 1999
- C9. Taylor R. Diabetic retinopathy for the team. *Diabetic Medicine* 2000
- C10. Taylor R. Early defects in insulin secretion and insulin action in the pathogenesis of type 2 diabetes mellitus. *International Diabetes Monitor* 12:18-19, 2000
- C11. Taylor R. Medical Masterclass. *Clinical Medicine* 2:165, 2002
- C12. Taylor R. Blood pressure and cardiovascular risk in the HOPE study. *Lancet* 359: 2117-8, 2002
- C13. Taylor R. Interleukin 10 production and type 2 diabetes. *International Diabetes Monitor* 15:23-24, 2003
- C14. Taylor R. Screening for diabetic retinopathy. *Lancet* 361: 1570, 2003
- C15. Taylor R. Conundrum of the HOPE study. *Brit Med J* 327: 681-82, 2003
- C16. Taylor R. Insulin delivery by alternative routes. *Practical Diabetes* 21: S1-, 2004
- C17. Brown M, Boon N, Brooks N, Brown E, Camm J, Caulfield M, Chilvers E, Gibson J, Griffin G, Grossman A, Hall A, Hart G, Heagerty T, Home P, Hodgson H, Horton R, Hughes R, Khaw KT, Lazarus J, Leaper D, McCollum P, Monson J, O'Rahilly S, Rowlands B, Scott J, Sutton R, Taylor R, Watkins H, Wright N. Modernising medical careers, medical training application service, and the postgraduate medical education and training board: time for the emperors to don their clothes. *Lancet*. 2007 Mar 24; 369(9566):967-8
- C18. Taylor R, Arun CS. Affordable quality assurance in retinal screening. *Diabet Med*. 2007 Jun; 24(6):690-1
- C19. Brown M, Boon N, Brooks N, Camm J, Corris P, Caulfield M, Chilvers E, Ewan P, Gibson J, Griffin G, Grossman A, Hall A, Hart G, Heagerty T, Hodgson H, Home P, Hughes R, Khaw KT, Lazarus J, Leaper D, Monson J, O'Rahilly S, Rowlands B, Scolding N, Sutton R, Taylor R, Watkins H, Wright N. Medical training in the UK: sleepwalking to disaster. *Lancet* 2007 May 19; 369(9574):1673-5
- C20. Taylor R, Chen MJ. Mechanism of the Second Meal Phenomenon: Reply to Dr Knop. *Diabetes Care* 2011; 34:e45
- C21. Taylor R, Chen MJ. Mechanisms of the Second Meal Effect: Reply to Dr Rayner et al. *Diabetes Care* 2011; 34:e56
- C22. Taylor R. Insulin dose in diabetic ketoacidosis. Reply to Savage et al. *Diabetic Medicine* 2012; 28: 153-4. doi: 10.1111/j.1464-5491.2011.03398.x.
- C23. Taylor R. Reversing type 2 diabetes. Reply to Paisey et al. *Practical Diabetes* 2012
- C24. Taylor R. Raising a questioning eyebrow. *Diabetes Digest* 2014; 13:40-41

- C25. Hodson K, MacDougall M, Taylor R. Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. *Brit Med J* 2014 Mar 11th
- C26. Hodson K, MacDougall M, Taylor R. Treating gestational diabetes reduces perinatal morbidity. *Brit Med J* 2014 Apr 14; 348:g2690. doi: 10.1136/bmj.g2690. PMID: 24732140
- C27. Hollingsworth KG, Al-Mrabeih A, Steven S, Taylor R. Pancreatic triacylglycerol distribution in type 2 diabetes. *Diabetologia* 2015 Nov;58(11):2676-8. doi: 10.1007/s00125-015-3718-1. PMID: 26232098
- C28. Taylor R. Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously - The Conceptt study. NIHR web information 2017
<https://discover.dc.nihr.ac.uk/portal/article/4000866/fewer-large-babies-are-born-to-pregnant-woman-with-type-1-diabetes-if-their-glucose-was-monitored-continuously>
- C29. Taylor R. The new understanding of type 2 diabetes: simplicity revealed. *Revista Colombia de Endocrinología Diabetes & Metabolismo* 2018; 5: 33
- C30. Taylor R. Remission of type 2 diabetes by weight loss in a non-white population. *The Lancet* 2020 June; 8(6):458-459. doi: 10.1016/S2213-8587(20)301457-9. PMID: 32445729
- C31. Marchesini G, Taylor R. Genes and Lifestyle: Which of the Two is More Relevant in Driving NAFLD Progression? *Liver and Digestive Disease* 2021;9:39.
doi.org/10.1016/j.dld.2021.08.011
- C32. Roth J, Ashcroft FM., Wollheim et al. Voices: Insulin and beyond. *Cell Metabolism* 2021; 31:692-99
- C33. Lean MEJ, Taylor R, Sattar N. Determination of autoantibodies in type 2 diabetes: one simple way to improve classification. *Diabetologia* 2023 66(5): 958–959. DOI:10.1007/s00125-022-05863-7
- C34. Taylor R. Fasting diets and type 2 diabetes. Letter to *The Times* 30th June 2023, p26.
- C35. Taylor R. Commentary: Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial. *PracticeUpdate* 2023 <https://www.practiceupdate.com/content/diabetes-remission-and-relapse-following-an-intensive-metabolic-intervention-combining-insulin-glarginelixisenatide-metformin-and-lifestyle-approaches/155718/65/8/1>.
- C36. Taylor R. Letter: Similar early metabolic changes induced by dietary weight loss or bariatric surgery. *Diabetologia* 2024 2024; 67:2603-2604. doi: 10.1007/s00125-024-06268-4.

- C37. Taylor R. Invited commentary: Understanding mechanism of pre-diabetes in young people. *Lancet Diabetes & Endocrinology* 2025; 13:814-5.
[https://www.thelancet.com/journals/landia/article/PIIS2213-8587\(25\)00190-1](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00190-1)
- C38. Taylor R. invited commentary: The omnipotent liver – dealing with variation in food composition. *JCEM* 2025 In press <https://doi.org/10.1210/clinem/dgaf469>
- C39. Taylor R. Q&A on Type 2 diabetes remission. *Diabetes and Primary Care* 2026 online. <https://diabetesonthenet.com/diabetes-primary-care/qa-type-2-diabetes-remission/>
- C40. Taylor R. & Bakai C. Primary Care Type 2 Diabetes Remission Toolkit. Online 2026 <https://www.pcdosociety.org/guidance>
- C41.
.

Invited Lectures

1. Use of insulin analogues in analysis of the linkage between the insulin receptor and post-binding events. Symposium on post-binding events in insulin action. St. Thomas' Hospital, London, September, 1984
2. Initiation of insulin action in human adipocytes by monoclonal anti-receptor antibodies. Third International Symposium on Insulin Receptors, Madrid, November 1986
3. The insulin receptor and insulin resistance. Caledonian Endocrine Society Meeting, December 1986
4. Clinical aspects of insulin receptor function. IV Hvidore Symposium, Oslo, May, 1987
5. Non-insulin dependent diabetes - No longer the poor cousin. Croom Lecture of Royal College of Physicians of Edinburgh, November 1988
6. Treatment of hypertension in diabetes. Royal College of Physicians of Ireland, March 1989
7. Pathogenesis of non-insulin dependent diabetes. Institute of Endocrinology, Moscow, July 1989
8. Insulin treatment in diabetes - When and how. Royal College of Physicians of Glasgow, Oct 1989
9. Pregnancy and insulin dependent diabetes - change in insulin sensitivity and implications for management.

Clinical Nutrition Meeting, Leeds, Sept 1989

10. Management of diabetes in the future.
Royal College of Physicians of London, March 1990
11. Resistance to injection.
R.D. Lawrence Lecture of British Diabetic Association, April 1991
12. Insulin resistance and hypertension.
British Endocrine Society Meeting, Brighton, April 1991
13. Modulating insulin sensitivity in non-insulin dependent diabetes.
Frontiers in Diabetes Research, Steno Hospital, Copenhagen, May 1992
14. Management of non-insulin dependent diabetes.
Cambridge Ophthalmological Symposium, Cambridge, September 1992
15. Measuring glucose metabolism in man using nuclear magnetic resonance spectroscopy. Honyman-Gillespie Lecture, Edinburgh Medical School, October 1992.
16. NIDDM: Resistance to ideas or resistance to insulin?
Royal College of Physicians of Edinburgh Symposium, November 1992
17. Basic and clinical aspects of insulin resistance.
Portuguese Society for Endocrinology, Porto, December 1992
18. Insulin treatment in NIDDM: Lessons for pathogenesis.
Endocrine Grand Rounds, Yale University Medical School, June 1993
19. Metabolic abnormalities in NIDDM.
MCRS conference, London, March 1994
20. Aetiology of NIDDM and relationship to the metabolic syndrome.
U.K. Advanced Diabetes Course, Edinburgh, June 1994
21. Screening for diabetic retinopathy using the mobile non-mydratic camera.
BDA eye screening symposium, Exeter, October 1994
22. Therapeutic gaps in the current management of NIDDM.
Glaxo International Seminar, London, October 1994
23. Science and Sensibility in NIDDM.
Isle of Wight Diabetes Conference, October 1994
24. Breaking the taboo: Insulin for the non-insulin dependent.
Commonwealth Institute, London, December 1994
25. Management of diabetes in the elderly.

- British Geriatric Association Meeting, May 1995
26. Pathogenesis of NIDDM.
Norwich Diabetes Conference, June 1995
 27. Effective screening for diabetic retinopathy
British Diabetic Association Medical and Scientific Section Meeting. October 1995
 28. Insulin resistance
Royal College of Physicians of Edinburgh, February 1996
 29. Screening for diabetic retinopathy in primary care.
Royal College of Ophthalmologists, London, September 1996
 30. Lessons from human muscle cell culture.
International Diabetes Federation Meeting, Helsinki, July 1997
 31. Cultured human muscle: A microcosm of insulin action.
Kings College Hospital, October 1997
 32. Methods of assessing insulin sensitivity.
Royal College of Physicians, May 1998
 33. TNF alpha and its specific effects upon insulin action in muscle.
Insulin Action Meeting, Rome, October 1998
 34. Insulin treatment in Type 2 diabetes.
Royal College of Physicians of East India., Calcutta, February 1999
 35. The nature of Type 2 diabetes.
All India Diabetes Update. Bombay, February 1999
 36. Insulin sensitivity and fertility.
British Fertility Society, Newcastle, April 1999
 37. Pregnancy and diabetes: Reality dawns. Royal College of Physicians of Edinburgh
Teesside symposium, April 1999
 38. Control of post-prandial blood glucose: The potential of new treatments.
Glasgow Lilly pre-conference symposium, April 1999
 39. Pancreatic nemesis and rational management.
Tayside Diabetes Symposium, November 1999
 40. Pathophysiological basis for treatment of type 2 diabetes.
Italian Society for Diabetology, Bari, May 2000
 41. Role of hepatic glucose output in the development of hyperglycaemia in type 2 diabetes. International Workshop on Hepatic glucose Output. Copenhagen,

September 2000

42. Management of hyperglycaemic emergencies.
RCP Regional Meeting, November 2000
43. Elucidating the physiology and pathophysiology of human carbohydrate metabolism in vivo using MR spectroscopy.
International Society for Magnetic Resonance in Medicine, Glasgow, April 2001
44. Future treatment of diabetes.
Northallerton Diabetes Meeting, April 2001
45. Are there defects in hepatic insulin sensitivity in type 2 diabetes?
International Symposium on Insulin Receptors and Insulin Action, Geneva, May 2001
45. Epidemiology of microvascular complications of diabetes.
European Association for the Study of Diabetes Meeting, Glasgow, Sept 2001
46. Where does the food go in type 2 diabetes?
Egyptian Diabetes Group Meeting, Cairo, March 2002
47. Management of microvascular complications of diabetes.
International Conference on Ophthalmology, Sydney, April 2002
48. Muscle glycogen storage after eating in type 2 diabetes.
Third Dept of Medicine, Vienna, May 2002
49. Rollicks with metabolics.
KGMM Alberti retirement symposium, Newcastle, September 2002
50. Quality assurance in screening for diabetic retinopathy.
Hammersmith Hospital, November 2002
51. Effective eye screening: Translating the National Service Framework into practice.
Diabetes UK Annual Professional Meeting, Glasgow, March 2003
52. Storing energy: Postprandial choices and their consequences.
Mayo Clinic Grand Round, Rochester MN, June 2003
53. Preventing complications: What can you achieve?
Complications Symposium, ADA, New Orleans, June 2003
54. Alchemy and alternative routes of insulin administration.
Oxford Diabetes Symposium, July 2003
55. Effect of ruboxistaurin, a selective PKC beta inhibitor, on diabetic microvascular complications.
IDF Symposium: The Road Less Travelled: Diabetes Treatment Beyond Glucose,

Paris, August 2003

55. Metabolism and Diabetes Overview.
International Society for Magnetic Resonance in Medicine Workshop, Orlando, Sept 2003
56. Where did you put your breakfast?
Scottish Study Group for the Care of Diabetes in the Young. Pitlochry, Oct 2003
57. What do you do with your food?
Clinical Meeting, Oxford Centre for DEM, Oct 2003
58. Policy into Practice – NICE and the NSF for diabetes.
Clinical Care Symposium, Bristol, Nov 2003
59. Screening for Diabetic Retinopathy.
Primary Care Diabetes Conference, London, Jan 2004
60. Clinical effects of ruboxistaurin on diabetic microvascular complications.
Diabetes UK symposium, March 2004
61. Diabetic Retinopathy. Expert session, BES conference, Brighton 2004
62. Magnetic resonance: A new window on clinical investigation. Association of Physicians of Region No. 1., March 2004
63. Effective Screening for Diabetic Retinopathy. DIG Symposium, Weston super Mare, May 2004
64. Separating wheat from chaff: A toolkit to test clinical research publications.
Advanced Diabetes Course, Exeter, July 2004
65. Diabetic Retinopathy Screening. DIG Symposium, Newcastle, September 2004
66. Battling with sweetness. Prof JM Davison retirement symposium, Newcastle, November 2004
67. Quality Assurance in Retinal Screening. Kings Lynn Diabetes Meeting, November 2004
68. Vision in Diabetes: The Arnold Bloom Lecture. Diabetes UK Annual Meeting, Glasgow, 2005
69. This house believes that the National Screening Committee's proposals for retinal screening will not decrease the incidence of blindness in the population. Debate for Royal College of Ophthalmologists Annual Conference, Birmingham May 2005
70. Optimal management of hyperglycaemia in hospital and of hyperglycaemic emergencies. Oxford Advanced Diabetes Course, October 2005

71. Chennai Gold Medal Oration in Diabetes. Chennai, India, November 2005
72. Effective Prevention of Blindness due to Diabetes. WHO Workshop, Geneva, November 2005
73. Glycogen loading for athletes and others. Newcastle Diabetes Centre Seminars, Newcastle, February 2006
74. Type 2 diabetes: Can we control complications? Novartis Symposium, Athens, April 2006
75. Pregnancy and Diabetes in Newcastle 1985-2005: Management and Outcomes. Regional Obstetric Survey meeting, Newcastle July 2006
76. Control of diabetes in labour. Intra-Partum Study Day Newcastle, July 2006.
77. Mother and baby. GP Forum Newcastle, July 2006.
78. Fatty liver: Are we what we eat? Invited lecture International Diabetes Federation Meeting, Capetown, November 2006
79. The Metabolic Syndrome: Badge of Success for the Hunter Gatherer? British Society of Periodontology; Edinburgh, May 2007
80. Mass Spectrometry and the Secret of Life. Newcastle Scientific Facilities Lecture, March 2007
81. Aetiology of type 2 diabetes: The mist clears. New Perspectives Symposium, Edinburgh, June 2007
82. The Metabolic Syndrome in Clinical Practice, 50th Anniversary Symposium of Medical Faculty, Paraguay, August 2007
83. Diabetes and the Heart, 50th Anniversary Symposium of Medical Faculty, Paraguay, August 2007
84. Magnetic Resonance and Diabetes, 50th Anniversary Symposium of Medical Faculty, Paraguay, August 2007
85. Metabolic Syndrome. NE Obesity Forum, Newcastle, Nov 2007
86. Pathogenesis of type 2 diabetes: The role of the liver. Diabetes UK meeting, March 2008
87. Retinal screening in Diabetic Pregnancy. NICE Guideline Symposium, Royal College of Obstetricians and Gynaecologist, April 2008
88. Management of severe hyperemesis. MacDonald Obstetric Society, April, 2008
89. NICE Guidance on Type 2 Diabetes: Retinal Screening. RCP, June 2008

90. Management of diabetes in acute situations. Oxford Advanced Diabetes Course, October 2008
91. Application of MR spectroscopy to clinical questions. UK Trade and Investment Seminars, New Jersey, December 2008
92. Preventing the worst fear: Effective screening for retinopathy in diabetes. Federation of European Nurses in Diabetes, Vienna, September 2009
93. Diabetes management in hospital. Oxford Advanced Diabetes Course, October 2009
94. Metabolic insights into human activity and diabetes. RCP Update in General Medicine, Freeman Hospital, November 2009
95. Treatment options after metformin: thiazolidinediones. Diabetes UK meeting, Liverpool, March 2010
96. Endocrinology for Obstetricians. Royal College of Obstetrics and Gynaecology, London, May 2010
97. Exploring the reversibility of type 2 diabetes. Association of British Clinical Diabetologists, Newcastle, May 2010
98. Type 2 diabetes: A curable disease. St Andrews symposium, St Andrews, May 2010
99. Periodontal disease and diabetes. Colgate-Palmolive symposium. London, May 2010
100. New challenges in diabetes retinal screening. West of Scotland Ophthalmologists. Glasgow, June 2010
101. Magnetic Insights into Health and Disease. Jesmond Senior Men's Club, Newcastle upon Tyne, June 2010
102. Using steroids in the managements of severe hyperemesis gravidarum. First National Conference on Nausea and Vomiting in Pregnancy. Warwick, July 2010
103. Application of magnetic resonance techniques to clinical research. 6th Annual Conference of UK Clinical Research Facilities, Newcastle upon Tyne, July 2010
104. Use of oral hypoglycaemic agents in gestational diabetes. Southern Obstetric Medicine Symposium, Royal College of Physicians, London, December 2010
105. Closing in on the cause of type 2 diabetes. German Diabetes Institute, Dusseldorf, January 2011
106. Physician's perspective on epidemiology of diabetic retinopathy. Royal College of

Ophthalmologists, February 2011

107. Endocrinology for Obstetricians – Maternal Medicine Conference. Royal College of Obstetrics and Gynaecology, London, May 2011
108. Reversing type 2 diabetes: Insight into aetiology. Association of Physicians of Great Britain and Ireland, April 2011
109. Practical management of type 2 diabetes Nepal Diabetes Society, Kathmandu, December 2011
110. Preventing blindness in diabetes, Nepal Diabetes Society, Kathmandu, December 2011
110. Reversing the twin cycles of type 2 diabetes. Banting Lecture of Diabetes UK, Glasgow, March 2012
111. Type 2 diabetes is a reversible metabolic syndrome. New Zealand Endocrine society, Auckland, May 2012
112. The aetiology of gestational diabetes becomes clear. International Society for Obstetric Medicine, Oxford, July 2012
113. The nature of type 2 diabetes. The challenge of mitigating microvascular and macrovascular risk over the natural history of T2DM. ADA symposium, Philadelphia, June 2012
114. Reversing to Enlightenment. Heart UK Conference, Newcastle upon Tyne, June 2012
115. Magnetic resonance studies of the liver. Gordon Conference, Maine, August 2012
116. Watch Your Liver. British Chapter International Society for Magnetic Resonance in Medicine, September 2012
117. Eye screening – The role of BARS. British Association of Retinal Screeners Conference, Liverpool, September 2012
118. Eating through the myths: Food, Health and Happiness. Federation of European Nurses in Diabetes Annual Conference, Berlin, September 2012
119. Balancing risks and benefits in Type 2 Diabetes. European Association for the Study of Diabetes Symposium, Berlin, September 2012
120. Reversing type 2 diabetes by diet alone. “Thinner, Fitter, Faster” RCPE Conference, October 2012
121. Mechanism of metabolic benefit after bariatric surgery: It’s all food restriction. Controversies on Diabetes and Hypertension meeting, Barcelona, November 2012

122. Honey, I shrank the Hairy Bikers! British Association of Metabolic Surgeons, Glasgow, January 2013
123. Reversing to Enlightenment: Aetiology of Type 2 Diabetes. Cambridge University Metabolic Research Group Lecture, February 2013
124. Endocrinology in Pregnancy. Maternal Medicine Symposium, RCOG, March 2013
125. Type 2 diabetes: Can you reverse yours? Edinburgh Diabetes Group, March 2013
126. Long term reversal of type 2 diabetes by reducing liver fat. EASD Study Group, Helsinki, March 2013
127. The Management of Obesity and Bariatric Surgery. Gateshead Diabetes Masterclass, March 2013
128. Losing weight like the Hairy Bikers. Can You? Darlington Diabetes UK members forum, April 2013
129. Reversing type 2 diabetes. Can you? Norfolk and Norwich Diabetes Annual Meeting, May 2013
130. Type 2 diabetes. Durham Diabetes UK Meeting, May 2013
131. Therapeutic advances in type 2 diabetes. Asia-Pacific, Middle East and African Countries) Expert Forum, New horizons in cardio-metabolic medicine, May 2013
132. Type 2 Diabetes – Reversing the Irreversible. RCP Medicine Conference, Calcutta, October 2013
133. Life, Diabetes and Gliptins. RCP Medicine Conference, Calcutta, October 2013
134. Debate: Bariatric Surgery is The Cure for Type 2 Diabetes. 2nd Excellence in Diabetes Conference, Qatar, February 2014
135. How much Pie? Food, Health and Diabetes. Plenary lecture, Diabetes UK Annual Scientific Conference, March 2014
136. Preventing loss of sight in diabetes. Medicine and Me series, Royal Society of Medicine, March 2014
137. Reversing the twin cycles of diabetes. Medical Pilgrims Meeting, April 2014
138. Does calorie restriction decrease pancreatic fat and improve insulin secretion in type 2 diabetes? Royal Society of Medicine, May 2014
139. The Personal Fat Threshold and Type 2 Diabetes. Barts International Diabetes Symposium, May 2014
140. Reversing the Irreversible: Type 2 Diabetes and You. Newcastle University Public

Lecture, November 2014

141. Reversing the Irreversible: Type 2 Diabetes. Royal College of Physicians and Surgeons of Glasgow, November 2014
142. Finessing the fat: Switching type 2 diabetes on and off. Society for Endocrinology, London, January 2015
143. How do our Surgeries work in Diabetes? British Obesity and Metabolic Surgery Society, Newcastle upon Tyne January 2015
144. The Art of the Possible: Light Dawns on Type 2 Diabetes. Young Diabetologists Forum, London March 2015
145. Stepping over your personal fat threshold: Health and Type 2 Diabetes. Newcastle University Graduate society, Newcastle upon Tyne April 2015
146. Non- Alcoholic Fatty Liver Disease. Lilly Hot Topics meeting, Newcastle upon Tyne April 2015
147. EASD NAFLD Workshop, Newcastle upon Tyne May 2015
148. Obesity management strategies and the role of bariatric surgery in type 2 diabetes management. Novartis AMAC Meeting , Seoul, S Korea. May 2015
149. Recent Evidence for Lifestyle Intervention in Type 2 Diabetes. North East Diabetes Symposium, Newcastle upon Tyne June 2015
150. Reversing Type 2 Diabetes to Normal: The Art of the Possible. Grand Round, Auckland City Hospital, New Zealand. August 2015
151. Stepping over your Personal Fat Threshold. Auckland Endocrinologists. Auckland, New Zealand August 2015
152. Reversing the Irreversible: Type 2 Diabetes to normal metabolism. Cardiac Society of Australia and New Zealand. Melbourne August 2015
153. How much Pie? Simple Metabolism for Survivors. Cardiac Society of Australia and New Zealand. Melbourne August 2015
154. Do you use your glycogen stores? Cardiac Society of Australia and New Zealand. Melbourne August 2015
155. Reversing type 2 diabetes to normal: Stepping over the personal fat threshold. Association for the Study of Obesity. Glasgow, September 2015
156. Weight loss to restore Beta Cell Function: A cure for type 2 diabetes? British Association of Retinal Screeners. Bristol, September 2015

157. Gut hormone are innocent bystanders in the metabolic response to bariatric surgery. Cambridge Diabetes Symposium, November 2015
158. The 800 calorie hit: hype or highroad to long term health? Association of British Clinical Diabetologists, RCP, London, November 2015
159. Weight loss decreases pancreatic triglyceride specifically in type 2 diabetes. Diabetes care symposium, International Diabetes Federation Meeting, Vancouver, December 2015
160. Type 2 diabetes: A reversible metabolic syndrome. Wellington, New Zealand, January 2016
161. Stepping over the Personal Fat Threshold of Type 2 diabetes. The Harry Keen Rank Prize Lecture, Diabetes UK, Glasgow, March 2016
162. Managing Diabetes in Pregnancy. Royal College of Obstetrics and Gynaecology, London, March 2016
163. Type 2 diabetes: Newer insights on mechanisms. Pacific Rim Gold Meeting, Mumbai, March 2016
164. Lessons for childhood: Weight loss in type 2 diabetes. Northern Regional Paediatric Update Meeting, Gateshead, March 2016
167. Managing the Vascular risk associated with NAFLD: VLDL₁-TG. European Association for the Study of Diabetes workshop on NAFLD, Copenhagen, April 2016
168. Aetiology of type 2 diabetes: studying reversal to normal. Oxford Centre for Diabetes and Metabolism seminar, Oxford, April 2016
169. The George Murray Approach to type 2 diabetes: Care Report to Cure. Endocrine Society Meeting, Newcastle, May 2016
170. Understanding the research process: How to construct research questions from day-today clinical practice. Specialist Trainees' Research Day, Newcastle, July 2016
171. The aetiology of type 2 diabetes. Kerala Diabetes Society/RSSDI, Kochi, Kerala July 2016
172. Stepping over your personal fat threshold. Kerala Diabetes Society/RSSDI, Kochi, Kerala July 2016
173. The rumbustious journey from Royal Medical Society in 1974 to reversing diabetes in 2016. Edinburgh Royal Medical Society, September 2016

174. Tackling obesity. North East Obesity Forum. Gateshead, October 2016
175. Putting insulin resistance into context by dietary reversal of type 2 diabetes. Royal College of Physicians of Edinburgh Symposium. Edinburgh October 2016
176. What you need to know about pre-existing diabetes in pregnancy. Royal College of Obstetricians and Gynaecologists. London, November 2016
177. Reversing the Irreversible. Guild of Medical Writers. London, November 2016
178. Using diet and behaviour change rather than bariatric surgery for long term reversal of type 2 diabetes. Clinical Conundrums meeting, Royal College of Physicians. London, January 2017
179. What can the Sugar Tax achieve? Clinical Conundrums Meeting, Royal College of Physicians. London, January 2017
180. Update of progress on DiRECT. Hot Topics Symposium, Diabetes UK Annual Professional Meeting. Manchester 2017
181. Diabetes and Thyroid disease in pregnancy. Royal College of Obstetricians and Gynaecologists. London, April 2017
182. Physiology, Food and Type 2 Diabetes. The Samuel Gee Lecture of the Royal College of Physicians. London, April 2017
183. World diabetes. Medsin International UK meeting. Newcastle, April 2017
184. Degree of non-alcoholic fatty liver disease is the greatest biochemical abnormality in early type 2 diabetes. EASD NAFLD Workshop, May 2017
185. Achieving long term return to normal metabolism in type 2 diabetes: When, Why and How. ADIT Meeting, Belgrade, May 2017
186. Achieving normoglycaemia in type 2 diabetes without drugs. Paraguay Diabetes Conference, Asuncion July 2017
187. Gestational diabetes: The new understanding. Paraguay Diabetes Conference, Asuncion July 2017
188. Understanding type 2 diabetes as a reversible condition. Paraguay Diabetes Conference, Asuncion July 2017

189. Type 2 diabetes: a simple reversible state of calorie excess. Henning Beck Nielsen Retirement Symposium, Odense, September 2017
190. Durable reversal of beta cell failure by calorie restriction. EASD, Lisbon, September 2017
191. Aetiology of type 2 diabetes: a reversible condition. Indian National Endocrinology Conference, Kerala, September 2017
192. The Personal Fat Threshold of type 2 diabetes. Indian National Endocrinology Conference, Kerala, September 2017
193. Reversal of type 2 diabetes: Simplicity revealed. Swedish Diabetes Summit, Gothenburg, November 2017
194. Type 2 diabetes – Can strategies in adults be implemented in adolescence? British Society for Paediatric Endocrinology, November 2017
195. DiRECT – Identifying the cause of type 2 diabetes. Plenary Lecture, IDF, Abu Dhabi, December 2017
196. DiRECT - Metabolic mechanisms behind remission of type 2 diabetes. Plenary Lecture, IDF, Abu Dhabi, December 2017
197. Calorie restriction for long term remission of type 2 diabetes. RCP London Advanced Medicine Course, February 2018
198. DiRECT Knowledge: Aetiology and Reversibility of Type 2 Diabetes. Keynote Lecture, Oxford NIHR BRC Symposium, Oxford February 2018
199. Diabetes in Pregnancy. RCOG Maternal Medicine Course, London March 2018
200. Understanding the How and why of remission. Plenary symposium, Diabetes UK Annual Professional Conference. London March 2018
201. The DiRECT results – symposium report. Diabetes Insider Meeting for people with diabetes, London March 2018
202. Update on DiRECT: Results and Implications. ADIT Meeting, Dubrovnik, April 2018
203. Are we ready to move the diabetes control goal on to reversing? 3rd Latin American Congress on Endocrinology, Cartagena, April 2018

204. New anti-diabetic medication and cardiovascular risk: Enough evidence to change medical practice guidelines? 3rd Latin American Congress on Endocrinology, Cartagena, April 2018
205. DiRECT: The Future. Hot Topics in Diabetes, Portsmouth, May 2018
206. Understanding and management of type 2 diabetes into the future ABCD Meeting, Glasgow, May 2018
207. From understanding to action: A rational approach to type 2 diabetes. Faculte de la Sante Publique, Paris, May 2018
208. Nutritional management and prevention of type 2 diabetes. Swiss Re Conference, Zurich, June 2018
209. DiRECT impact on the understanding and future management of type 2 diabetes. Oxford Advanced Diabetes Course, Oxford, July 2018
210. Reversal of Type 2 Diabetes Throughout the Lifecourse. UK Congress on Obesity, Newcastle September 2018
211. Case finding for NAFLD/NASH. European Association for the Study of the Liver, Geneva, September 2018
212. DiRECT view on the future of type 2 diabetes management. Hot Topics Symposium, Lumley Castle, September 2018
213. What exactly is type 2 diabetes? Federation of European Nurses in Diabetes Meeting, Berlin, September 2018
214. DiRECT - A brighter future for people with type 2 diabetes. Novartis Symposium, EASD, Berlin, October 2018
215. The role of beta cell recovery in achieving reversal of human type 2 diabetes. 5th Banting and Best Diabetes Research Centre, Joslin Clinic and Danish Diabetes Academy Meeting, Copenhagen October 2018
216. Understanding the aetiology of type 2 diabetes using population scale remission. Von Mering Medal Lecture, Dusseldorf, October 2018
217. The Energy Crisis and type 2 diabetes. Human Nutrition Research Centre Research day, Newcastle, October 2018
218. Food and type 2 diabetes: Restoring the milieu interieur. European Genomic Institute For Diabetes, Lille, December 2018
219. NU retired staff, December 2018

220. The new approach to treating type 2 diabetes. Amble & Warkworth Diabetes UK Group, January 2019
221. Long term reversal of type 2 diabetes: separating metabolic from human factors. Swedish Endocrine Society Annual Meeting, Sweden, February 2019
222. Diabetes UK Professional Conference, March 2019
223. Fourth African Diabetes Congress, Yaounde, April 2019
224. Faculty of the 4th World Congress on Interventional Therapies for T²D, New York, April 2019
224. Reversing diabetes – the story of the DiRECT trial and the 800 calorie diet. National Diabetic Eye Screening Conference, London, April 2019
225. AACE – 28th Annual Scientific & Clinical Congress, Los Angeles, April 2019
226. LifeCycle, Malta, May 2019
227. Reversing to enlightenment: Type 2 diabetes. ICM Director’s Day, May, 2019
228. Diet as a cure of type 2 diabetes – Lessons from the DiRECT study. Diabetes Congress 2019, Berlin, May 2019
229. Diabetes, Remission of Type 2 Diabetes for Two Years Is Associated with Full Recovery of Beta-Cell Functional Mass in the Diabetes Remission Clinical Trial (DiRECT). ADA 79th Scientific Symposium, San Francisco, June 2019
230. Prospective Study to Personal Threshold. Oxford Symposium, Keble College, Oxford, Jul 2019
231. EASD, Barcelona, September 2019
232. Real-time physiology using magnetic resonance techniques: Defining the aetiology of type 2 diabetes. Academic Doctors, Newcastle University, October 2019
233. Type 2 Diabetes Population Intervention. Spark Workshop, Netherlands Centre of Lifestyle Medicine. Leiden, October 2019
234. DiRECT study. Trend UK Diabetes Nursing Conference 2019, London, October 2019
235. Remission of T2DM: is it real and feasible? Seventh Mantova Workshop on Diabetes Mellitus and Related Conditions, Italy, October 2019

236. The new understanding of type 2 diabetes and future challenges. HNRC 25th Anniversary conference, Newcastle University, October 2019
237. The simplicity of type 2 diabetes – and what to do about it. Diabetes Professional Care Conference, London, October 2019
238. Low calorie diets to treat obesity and Type 2 diabetes. Diabetes Professional Care Conference, London, October 2019
239. Changing gear for good and driving T2DM in reverse. RCGP Conference, Newcastle, October 2019
240. Physiological basis of the aetiology and reversal of type 2 diabetes: Relevance to Primary Care management. Finnish Diabetes day, Helsinki, November 2019
241. Reversing type 2 diabetes in the real world. Derby Medical Society, Derby, January 2020
242. Making things happen. Policy Academy Fellows Programme 2020, Newcastle University, February 2020
243. The new understanding of type 2 diabetes. 4th International Diabetes Summit, Pune, India March 2020
244. Practical achievement of remission of type 2 diabetes. 4th International Diabetes Summit, Pune, India March 2020
245. Clinical aspects of long term remission of type 2 diabetes. American Diabetes Association Annual Scientific Sessions, Chicago (virtual), June 2020
246. The new understanding of type 2 diabetes: A reversible condition. St Petersburg (virtual), September 2020
247. Remission of T2DM: Mechanistic Lessons from Counterpoint, Counterbalance and DiRECT. The Obesity Society Annual Meeting, San Diego (virtual), November 2020
248. Averting the looming global pandemic – lessons from the DiRECT, Counterpoint and Counterbalance Research Studies. American College of Lifestyle Medicine Annual meeting, Atlanta, Georgia, November 2020
249. Aetiology of type 2 diabetes and its practical implications. Guest lecture, University of The Pacific, California, December 2020
250. T2DM: Simple etiology but heterogenous individuals. 2021 Keystone Symposia on Obesity, USA. January 2021

251. Type 2 diabetes: The other elephant in the room. Sir Robert W Philip Lecture of The Royal College of Physicians of Edinburgh, March 2021
252. Promises and Pitfalls of type 2 diabetes remission. Chelleram International Diabetes Symposium, Pune, March 2021
253. Does type 2 diabetes differ between ethnicities? Chelleram International Diabetes Symposium, Pune, March 2021
254. Type 2 diabetes in the real world: From understanding aetiology to practical treatment. ADIT Conference (virtual), March 2021
255. Understanding aetiology of type 2 diabetes underpins the practical details for remission. Netherlands Obesity Meeting, Utrecht, April 2021
256. Low carb diet in type 2 diabetes in children and young people: Can we learn from adult colleagues? Diabetes UK symposium, April 2021.
257. 2021 Practical Management of Type 2 Diabetes - Guided By its Simple Aetiology. All India Crossconnect Conference, May 2021.
258. Aetiology of type 2 diabetes revealed by studies of onset and remission. Netherlands Lifestyle Medicine Conference, June 2021
259. Magnetic resonance insights to practical therapy: Achieving effective weight loss and remission of type 2 diabetes. American Diabetes Association symposium on type 2 diabetes remission, June 2021
260. How and why type 2 diabetes can be reversed to normal. Oxford Ophthalmology Conference, Oxford, July 2021
261. Understanding the cause of type 2 diabetes – and remission. Australia Diabetes Summit, July 2021
262. Remission of type 2 diabetes: the vital role of weight loss. 1 Cumbre Virtual Internacional Cardiometabólica y Renal, 2ª Reunión Regional Virtual de Cardiología 2021 y 13ª Conferencia Científica Anual sobre Síndrome Metabólico, Mexico, July 2021
263. Achieving long term remission of type 2 diabetes via knowledge of aetiology. British Society of Lifestyle Medicine: Edinburgh 2-4 September 2021
264. The aetiology of type 2 diabetes and its application to routine treatment. Keynote lecture at DDZ annual research symposium, Dusseldorf, October 2021
265. Should Metformin be the 1st line monotherapy of T2DM? ABCD Debate, October 2021

266. Type 2 diabetes remission possible – Why and How. Society for Endocrinology Annual Meeting, Edinburgh, November 2021
267. Reversal of Type 2 Diabetes: The Current Position. Diabetes Professional Conference, London, November 2021
268. Living Without Diabetes. Freedom From Diabetes Muktotsav, India, December 2021
269. Etiology of type 2 diabetes. University of California Grand Rounds. Davis USA, January 2022
270. Remission of type 2 diabetes – practical insights. Emirates Diabetes Society Conference, Dubai, February 2022
271. Thresholds for metabolic effects of NAFLD across the BMI range. NAFLD Workshop May 2022
272. Understanding type 2 diabetes across the BMI range. Diabetes India online conference, May 2022
272. The root cause of type 2 diabetes – irrespective of BMI. Peking University Diabetes Forum, May 2022
273. Type 2 diabetes: From hypothesis to NHS remission programme. European Endocrine Conference, Milan May 2022
274. Temporal aspects of remission of type 2 diabetes. American Diabetes Association, New Orleans, June 2022
275. Fat - the problem and the solution. ABCD Insulin Centenary Meeting, London July 2022
276. Eyes wide open – Type 2 diabetes. British Association of Retinal Screeners, annual meeting September 2022
277. Mechanisms of weight loss induced remission in people with type 2 diabetes but normal BMI. EASD September 2022
278. Type 2 diabetes: Now understandable all the way to remission. Diabetes Professional Care Conference. November 2022
279. Research to Clinical Practice. Annual Tyneside Retinal Screening Meeting. December 2022

280. Remission of Type 2 Diabetes – Fact and Fiction. International Diabetes Conference, Dubai Feb 2023
281. Getting real about food and exercise in type 2 diabetes. International Diabetes Conference, Dubai Feb 2023
282. The myth of heterogeneity in type 2 diabetes. Chelleram International Diabetes Conference, Pune, India March 2023
283. Getting the balance between food and exercise in type 2 diabetes. Chelleram International Diabetes Summit, Pune, India March 2023
284. Remission of type 2 diabetes – pathophysiology and practicality. Department of Medicine, Tubingen University Medical School
285. Remission of type 2 in people with lower body weight: The ReTune study. Diabetes UK Professional Conference, Liverpool April 2023
286. 5 year outcomes of the DiRECT study. Diabetes UK Professional Conference, Liverpool April 2023
287. Achieving remission in type 2 diabetes. Association of Children’s Diabetes Conference, Birmingham, May 2023
288. Understanding type 2 diabetes and its remission. Public Health Conference, Sheffield, May 2023
289. Remission of Type 2 Diabetes – Pathophysiology and Practicality Tubingen, Germany May 2023
290. Achieving remission in type 2 diabetes. Aalborg, Sweden May 2023
291. Weight loss via an acceptable low calorie diet:Insight into the causative mechanisms of type 2 diabetes. American Diabetes Association, San Diego, June 2023
292. Mechanism of type 2 diabetes reversal. ESPEN meeting, Lyon, France Sept 2023
293. Life Without Diabetes. Primary Care Diabetes Society, Birmingham, Sept 2023
294. Role and determinants of individual tolerability of ‘obesity’ in diabetes development: Lessons from the Twin Cycle Hypothesis. EASD Hamburg, Sept 2023
295. Demystifying Type 2 Diabetes. Diabetes Australia. Zoom Lecture, Nov 2023
296. Type 2 Diabetes: From Twin Cycle Hypothesis to NHS England National Remission Program. Joslin Clinic Grand Rounds Boston, US. Dec 2023

297. The Twin Cycle Hypothesis: From concept to routine application for type 2 diabetes remission. Physiological Society. Manchester UK Mar 2024
298. The holy grail - diabetes remission: Lessons from DiRECT and beyond. European Young Diabetologist forum. Bologna, Apr 2024
299. What we learned from the DiRECT trial. European Congress on Obesity. Venice May 2024
300. Achieve remission! ADA Scientific Sessions symposium. Orlando June 2024
301. Long term remission: Lessons from DiRECT. Satellite Symposium, ADA Scientific Sessions. Orlando June 2024
302. Type 2 diabetes: An experimental medicine odyssey. Claude Bernard lecture, EASD. Madrid Sept 2024
303. Type 2 diabetes: Getting real about body mass index. Augusto D. Litonjua Endowed Lecture, Philippines Diabetes Association Manila Nov 2024
304. Pathophysiology Of Type 2 Diabetes Reversal and Ongoing Remission. 4th Malaysian Lifestyle Conference, Kuala Lumpur Nov 2024
305. Body weight and type 2 diabetes: Seeing the wood from the trees. Rural GP Assoc of Scotland, Inverness Nov 2024
306. Type 2 Diabetes: Achieving Remission. Barbados Diabetes Society and The University of the West Indies, Bridgetown Nov 2024
307. Type 2 diabetes in 2024: A frameshift in knowledge and management. Mount Sinai School of Medicine Grand Round, New York Jan 2025
308. Effective management of type 2 diabetes: How to achieve remission. Congresso Portugues de Endocrinologia, Porto, Jan 2025
309. The holy grail - diabetes remission: Lessons from DiRECT and beyond. China Young Diabetologist Forum, Beijing China, March 2025
310. Management of cardio-renal-metabolic syndrome in type 2 diabetes. European Association of Preventive Cardiology online Educational lecture May 2025
311. Remission vs reversal vs cure: Do we need new language to match clinical realities in 2025? EASD, Vienna, Sept 2025. EASD invited lecture.
312. Maximizing Cardiovascular-Kidney Benefit by aiming at normoglycemia: the DIRECT Study Paradigm. EASD invited lecture.

313. T2D: a condition of homogenous aetiology in genetically heterogenous people. Regional Update meeting, Birmingham October 2025
314. Achieving long-term remission of type 2 diabetes in the real world. Royal College of Physicians Regional Update, Reading, October 2025
315. Cutting through the food / health confusion. Public lecture St George's Church, Newcastle upon Tyne October 2025
316. Cardiovascular disease and type 2 diabetes remission. NHS Professional meeting Olympia, London October 2025.
317. Weighty matters – pre-operative and pre-delivery management. Scottish Association of Anaesthetists, Perth November 2025.
318. Testing hypotheses using bits and bytes. The 2025 NUTRIM lecture, *Institute of Nutrition and Translational Research in Metabolism, Maastricht University. Maastricht November 2025*
391. Type 2 Diabetes Today and Tomorrow: Innovations that transform clinical practice. Panama Diabetes Symposium, Panama City March 2026
392. Beyond glucose: How weight management refines the treatment of type 2 diabetes. Panama Diabetes Symposium, Panama City March 2026
393. Remission in Type 2 Diabetes. Österreichische Diabetes Gesellschaft Strategy Meeting. Riegersburg March 2026.

Clinical Work

I carried a full time clinical commitment as Head of Clinical Unit until 2003 when the balance of academic and clinical work changed to allow increased focus upon metabolic research and magnetic resonance spectroscopy. From 1985 to 2016, outpatient work in Obstetric Diabetes, General Diabetes, Retinal Screening and General Medicine occupied 50% of the working week.

My Diabetes Service was developed to be at the forefront of clinical care and to provide excellent training for junior doctors. Audit and reaudit of my Coronary Care, peri-operative and acute medical admission diabetes guidelines led to major improvements in clinical care. The weekly post-clinic case discussion meeting allowed dissemination of knowledge and ensured a uniformity of clinical management in the service. The Mobile Retinal Camera service to screen for diabetic retinopathy was established by myself in

1986 and I continued to provide advice and a rapid track to treatment for the Region. In 2000 I introduced a digital screening system using high resolution equipment, this being the only such advanced system at the time in the UK. I raised funds following the success of the Newcastle unit to carry out a multicenter study, establishing 11 other mobile units nationwide. The resulting data from the 64,000 Screening Episodes study led directly to the establishment of a national retinal screening programme. The effective prevention of blindness due to diabetes was demonstrated first in Newcastle and later throughout England, with diabetes being shown to be no longer the leading cause of avoidable blindness in the working age population.

I ran the medical obstetric service for the combined Newcastle Obstetric Unit until 2016, and with outpatient clinics in addition to inpatient and emergency work. Clinical research was published on the optimum management of diabetic pregnancy and labour. Observational studies on the role of high-dose steroids in the management of hyperemesis gravidarum led to the 2015 Green Top Guideline on this condition from Royal College of Obstetrics & Gynaecology. This highly effective and safe treatment for severe hyperemesis is now accepted in the UK, and termination is no longer regarded as the only option. Weight loss during pregnancy for gestational diabetes was introduced as a clinical management option.

Particular Achievements

Research

1. Elucidation of the aetiology of type 2 diabetes followed formal testing of the Twin Cycle Hypothesis in the Counterpoint Study, and this was published in 2011. This has subsequently been corroborated and extended by the Counterbalance, Pancreas, DiRECT and ReTUNE studies. Importantly, this research thrust has led directly to an ADA/EASD/DUK consensus statement defining remission of type 2 diabetes (2021).
2. The Counterpoint study's demonstration that type 2 diabetes is a reversible metabolic syndrome dependent upon the excess fat exposure of pancreas and liver has had direct impact upon care of people with type 2 diabetes, and has also empowered many around the world to lose weight and reverse their own diabetes. Followed by the Counterbalance, Pancreas and DiRECT studies, it resulted in the establishment of a National NHS pilot scheme (started 2021) and a full national Type 2 Diabetes Path to Remission Programme (2025).
3. Demonstration of the involuted whole pancreas in type 2 diabetes but with recovery of both pancreas volume and morphology during prolonged remission of type 2 diabetes.
4. Demonstration of the uniform aetiology of type 2 diabetes in people with normal or raised BMI and that weight loss-induced return to normal function was determined by the same pathophysiologic changes as for heavier people.
5. Application of ^{13}C magnetic resonance spectroscopy to determine the role of skeletal muscle and liver in acute storage of meal derived substrate in normal and diabetic man which, in more insulin resistant individuals is inadequate. This leads to disposal of meal derived glucose by *de novo* lipogenesis and accumulation of saturated fat in liver.
6. Demonstration of insulin responsive and unresponsive phases in the post-exercise recovery of muscle glycogen stores in man.

7. Development and application of stable isotope methodology for the assessment of post-prandial hepatic glucose output in health and disease.
8. Contribution to knowledge and development of concepts relating to the processes of insulin signalling in muscle of normal and diabetic humans:
 - Development of human myoblast culture to permit work on the insulin signalling defect in NIDDM.
 - Proof of the intrinsically inherited nature of tissue insulin insensitivity using cells passaged in culture from individuals with and without family histories of NIDDM.
 - Elucidation of the degree of lack of insulin responsiveness of muscle glycogen synthase in Caucasian NIDDM and the effect of conventional treatment upon this.
 - Demonstration of unique nature of insulin signalling in individual cell types.
 - Demonstration of separate modulation of insulin receptor activity and post-binding pathway regulation.
7. Documentation of the natural history of diabetic retinopathy and effect of screening upon blindness rates. Impact of effective quality assurance systems in retinal screening. Establishment of a National Eye Screening Programme with subsequent sharp decrease in national rates of blindness due to diabetes.

Clinical Medicine

1. Demonstration of the reversible nature of type 2 diabetes, in people of all BMI levels. I have guided this research from initial hypothesis to achieve a paradigm shift in NHS clinical management. There is now a fully funded Path to Remission service for all with type 2 diabetes within 6 years of diagnosis.
2. Development of technology and clinical system to support the prototype mobile retinal screening vehicle with subsequent demonstration of the sensitivity and specificity of the technique in screening for sight-threatening diabetic retinopathy. The Handbook of Retinal Screening in Diabetes (successor to A Practical Guide to Polaroid Retinal Photography) is in widespread use in its second edition. The interactive CD-ROM on retinopathy broke new ground as a means of communicating impact of treatment upon patients. The innovative digital screening system has attracted widespread attention and a National screening system has resulted from my original research. Diabetes is no longer the commonest cause of blindness in the working age population of the UK. Co-founding the British Association of Retinal Screeners has led to recognition of screeners as a distinct professional body, and this association is now large and thriving.
3. Establishment of nationally recognised Out-Patient Diabetes Service conducive to modern patient care as well as undergraduate and postgraduate teaching.
4. Development of a national noted obstetric medical service. In particular, the optimum management of diabetic pregnancy and the management of hyperemesis gravidarum using prednisolone has been established. Practical guidelines on management of life-threatening hyperemesis have been published both in person and by the Royal College of Obstetrics and Gynaecology.
5. Publication of books written for lay people and doctors to popularize and permit sound management for all with type 2 diabetes.

Teaching

1. The success of my introduction of the first systematic Clinical Methods teaching course

in 1984 led to the opening of the Newcastle Clinical Skills Laboratory in 1994 together with an innovative system for clinical skills teaching as part of the new (1994) Newcastle clinical curriculum. This was subsequently nationally recognised as being outstanding (24/24 in the National Teaching Quality Assessment exercise). The Clinical Skills Course which I directed until 2006 remained a central part of the Newcastle clinical curriculum for many years.

2. As deputy Director Teaching for Newcastle Hospitals I developed a system for evaluation of quality of clinical teaching and hence driving up quality of delivery.
4. Establishment and supervision of a practical retinal screening training programme for retinal screeners in Newcastle. Expansion of this to train retinal screeners from the northern half of the UK during the establishment phase of the National Programme.
5. Delivering innovative Science into Schools Programme to encourage children to consider careers in physics in relation to Medicine.
6. Postgraduate lectures nationally and internationally, informing doctors and scientists of best clinical practice based on clarity in communicating understanding of metabolism.

Management

1. Management of successful fundraising (£5.2 million) to build the Newcastle Magnetic Resonance Centre and to establish the Newcastle University Chair in Medical Resonance Physics. Subsequent fundraising of £1.5 million to install the second 3T whole body scanner in 2014.
2. Directorship of Newcastle Magnetic Resonance Centre from August 2005 to March 2020. This involved the *de novo* set up of this new research centre. In particular, building the team of physicists to drive innovation of techniques has been outstandingly successful not only for diabetes but also for other disciplines. Following opening the MR Centre, it was possible to acquire funding to build the adjacent Clinical Ageing Research Unit (CARU). A new University Campus has now been constructed around the Centre as a direct consequence of these developments. All three senior physicists originally recruited to set up the MR Centre still are working at Newcastle University.
3. Advice upon management of retinal screening services throughout the UK and achieving coordinated national action has resulted in the present UK system of screening.
4. Enlisting the cooperation of all physicians and surgeons in the Region was a major management exercise to produce a coordinated team able to deliver the highly successful 1994 Clinical Skills course that I devised as the basis for the new curriculum, alongside the new regionalized final year clinical placement in Medicine.
5. Management by motivation and leadership of both research and clinical teams has permitted innovation and consistent achievement of specific goals in excess of that consistent with resource availability.
6. Participation in the NHSE Type 2 Diabetes Path to Remission Advisory Body and the Scientific Advisory Committee on Low Carbohydrate Diets in Type 2 Diabetes.
7. Chairman of Trial Steering Groups for DiGEST (2018-2024) and LEGEND studies (2024-2027).